UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, ~~2022~~2023

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number: 001-36329

Societal CDMO, Inc.

(Exact name of registrant as specified in its charter)


Pennsylvania	26-1523233
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1 E. Uwchlan Ave, Suite 112, Exton, Pennsylvania	19341
(Address of principal executive offices)	(Zip Code)

(770) 534-8239

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of exchange on which registered
Common Stock, par value $0.01	SCTL	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August ~~3, 2022,~~7, 2023, there were ~~56,657,860~~90,127,280 shares of common stock, par value $0.01 per share, outstanding.

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION		1
Item 1. Financial statements	��	1
Item 2. Management's discussion and analysis of financial condition and results of operations		1819
Item 3. Quantitative and qualitative disclosures about market risk		2627
Item 4. Controls and procedures		2627
PART II. OTHER INFORMATION		2728
Item 1. Legal proceedings		2728
Item 1A. Risk factors		2728
Item 2. Unregistered sales of equity securities and use of proceeds		2830
Item 3. Defaults upon senior securities		2830
Item 4. Mine safety disclosures		2830
Item 5. Other information		2830
Item 6. Exhibits		2830
SIGNATURES		3032

PART I. FINANCIAL INFORMATION

Item 1. Financial statements

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(Unaudited)


(amounts in thousands, except share and per share data)	June 30, 2022			December 31, 2021			June 30, 2023			December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	15,481		$	25,217		$	4,703		$	14,995
Accounts receivable, net		16,524			11,913			15,522			15,950
Contract asset		9,359			8,565
Contract assets								7,747			8,724
Inventory		8,366			8,917			12,859			10,301
Prepaid expenses and other current assets		2,245			2,917			2,988			2,848
Assets held for sale								2,802			2,768
Total current assets		51,975			57,529			46,621			55,586
Property, plant and equipment, net		50,957			51,708			51,212			50,365
Operating lease asset		5,712			5,924			5,254			5,491
Intangible assets, net		3,392			3,833			2,576			2,928
Goodwill		41,077			41,077			41,077			41,077
Other assets		246			246			1,996			1,996
Total assets	$	153,359		$	160,317		$	148,736		$	157,443
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$	2,336		$	2,085		$	3,929		$	1,466
Current portion of related party debt		2,039			2,039
Current portion of debt								7,148			7,577
Current portion of operating lease liability		1,069			1,055			1,093			1,079
Accrued expenses and other current liabilities		7,784			12,556			7,137			12,686
Total current liabilities		13,228			17,735			19,307			22,808
Debt, net of current portion		94,360			92,127			31,010			30,967
Related party debt, net of current portion		3,586			3,369
Operating lease liability, net of current portion		4,769			4,932			4,381			4,584
Other liabilities		87			90			39,720			39,225
Total liabilities		116,030			118,253			94,418			97,584
Commitments and contingencies (note 7)
Shareholders’ equity:
Preferred stock, $0.01 par value. 10,000,000 shares authorized, NaN issued or outstanding		0			0
Common stock, $0.01 par value. 95,000,000 shares authorized, 56,644,563 and 46,681,453 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		566			467
Convertible preferred stock, $0.01 par value. 10,000,000 shares authorized, 0 and 450,000 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively								—			4,350
Common stock, $0.01 par value. 185,000,000 shares authorized, 90,046,925 and 84,588,868 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively								900			846
Additional paid-in capital		289,900			287,351			326,949			320,298
Accumulated deficit		(253,137	)		(245,754	)		(273,531	)		(265,635	)
Total shareholders’ equity		37,329			42,064			54,318			59,859
Total liabilities and shareholders’ equity	$	153,359		$	160,317		$	148,736		$	157,443

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(Unaudited)

Three months ended June 30,

Six months ended June 30,

(amounts in thousands, except share and per share data)
2022

2021

2022

2021

Revenue
$
23,152

$
18,017

$
44,346

$
34,820

Operating expenses:

Cost of sales (excluding amortization of intangible assets)

17,470

12,334

33,584

26,671

Selling, general and administrative

5,160

3,787

10,870

8,470

Amortization of intangible assets

220

54

441

700

Total operating expenses

22,850

16,175

44,895

35,841

Operating income (loss)

302

1,842

(549
)

(1,021
)
Interest expense

(3,421
)

(3,960
)

(6,834
)

(7,858
)
Gain on extinguishment of debt

—

3,352

—

3,352

Net (loss) income
$
(3,119
)

$
1,234

$
(7,383
)

$
(5,527
)

(Loss) income per share, basic and diluted
$
(0.06
)

$
0.03

$
(0.13
)

$
(0.16
)

Weighted average shares outstanding

Basic

56,598,706

39,018,730

56,475,626

34,403,935

Diluted

56,598,706

39,352,054

56,475,626

34,403,935


	Three months ended June 30,						Six months ended June 30,
(amounts in thousands, except share and per share data)	2023			2022			2023			2022
Revenue	$	21,799		$	23,152		$	43,326		$	44,346
Operating expenses:
Cost of sales		17,327			17,470			36,606			33,584
Selling, general and administrative		5,272			5,160			9,934			10,870
Amortization of intangible assets		168			220			352			441
Total operating expenses		22,767			22,850			46,892			44,895
Operating (loss) income		(968	)		302			(3,566	)		(549	)
Interest expense		(2,314	)		(3,430	)		(4,459	)		(6,848	)
Interest income		109			9			240			14
Loss before income taxes		(3,173	)		(3,119	)		(7,785	)		(7,383	)
Income tax expense		39			—			111			—
Net loss	$	(3,212	)	$	(3,119	)	$	(7,896	)	$	(7,383	)

Loss per share, basic and diluted	$	(0.04	)	$	(0.06	)	$	(0.09	)	$	(0.13	)

Weighted average shares outstanding, basic and diluted		87,330,496			56,598,706			86,072,074			56,475,626

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Statements of Shareholders’ Equity or Deficit

(Unaudited)


	Common stock				Additional paid-in			Accumulated						Convertible preferred stock						Common stock				Additional paid-in			Accumulated
(amounts in thousands, except share data)	Shares		Amount		capital			deficit			Total			Shares			Amount			Shares		Amount		capital			deficit			Total
Balance, December 31, 2021		46,681,453	$	467	$	287,351		$	(245,754	)	$	42,064
Issuance of common stock, net of costs		9,302,718		93		(109	)		—			(16	)
Stock-based compensation expense		—		—		1,479			—			1,479
Vesting of restricted stock units, net		487,695		5		(106	)		—			(101	)
Exercise of stock options		220		—		—			—			—
Net loss		—		—		—			(4,264	)		(4,264	)
Balance, March 31, 2022		56,472,086	$	565	$	288,615		$	(250,018	)	$	39,162
Issuance of common stock, net of costs		—		—		(113	)		—			(113	)
Balance, December 31, 2022															450,000		$	4,350			84,588,868	$	846	$	320,298		$	(265,635	)	$	59,859
Issuance of stock, net of costs															—			(18	)		—		—		(18	)		—			(36	)
Stock-based compensation expense		—		—		1,408			—			1,408			—			—			—		—		1,044			—			1,044
Vesting of restricted stock units, net		172,477		1		(10	)		—			(9	)		—			—			313,450		3		(210	)		—			(207	)
Net loss		—		—		—			(3,119	)		(3,119	)		—			—			—		—		—			(4,684	)		(4,684	)
Balance, June 30, 2022		56,644,563	$	566	$	289,900		$	(253,137	)	$	37,329

Balance, December 31, 2020		28,601,358	$	286	$	219,998		$	(234,384	)	$	(14,100	)
Issuance of common stock, net of costs		2,202,420		22		9,318			—			9,340
Balance, March 31, 2023															450,000		$	4,332			84,902,318	$	849	$	321,114		$	(270,319	)	$	55,976
Conversion of preferred stock															(450,000	)		(4,332	)		4,500,000		45		4,287			—			—
Stock-based compensation expense		—		—		3,133			—			3,133			—			—			—		—		1,593			—			1,593
Vesting of restricted stock units, net		209,541		2		(338	)		—			(336	)		—			—			644,607		6		(45	)		—			(39	)
Net loss		—		—		—			(6,761	)		(6,761	)		—			—			—		—		—			(3,212	)		(3,212	)
Balance, March 31, 2021		31,013,319	$	310	$	232,111		$	(241,145	)	$	(8,724	)
Issuance of common stock, net of costs		15,333,332		153		31,950			—			32,103
Stock-based compensation expense		—		—		1,929			—			1,929
Vesting of restricted stock units, net		155,198		2		(128	)		—			(126	)
Net income		—		—		—			1,234			1,234
Balance, June 30, 2021		46,501,849	$	465	$	265,862		$	(239,911	)	$	26,416
Balance, June 30, 2023															—		$	—			90,046,925	$	900	$	326,949		$	(273,531	)	$	54,318


Balance, December 31, 2021	—	$	—	46,681,453	$	467	$	287,351		$	(245,754	)	$	42,064
Issuance of stock, net of costs	—		—	9,302,718		93		(109	)		—			(16	)
Stock-based compensation expense	—		—	—		—		1,479			—			1,479
Exercise of stock options, net	—		—	220		—		—						—
Vesting of restricted stock units, net	—		—	487,695		5		(106	)		—			(101	)
Net loss	—		—	—		—		—			(4,264	)		(4,264	)
Balance, March 31, 2022	—	$	—	56,472,086	$	565	$	288,615		$	(250,018	)	$	39,162
Issuance of common stock, net of costs	—		—	—		—		(113	)		—			(113	)
Stock-based compensation expense	—		—	—		—		1,408			—			1,408
Vesting of restricted stock units, net	—		—	172,477		1		(10	)		—			(9	)
Net loss	—		—	—		—		—			(3,119	)		(3,119	)
Balance, June 30, 2022	—	$	—	56,644,563	$	566	$	289,900		$	(253,137	)	$	37,329

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(Unaudited)


	Six months ended June 30,						Six months ended June 30,
(amounts in thousands)	2022			2021			2023			2022
Cash flows from operating activities:
Net loss	$	(7,383	)	$	(5,527	)	$	(7,896	)	$	(7,383	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		2,887			5,062			2,637			2,887
Non-cash interest expense		2,530			3,080			624			2,530
Depreciation expense		3,594			3,033			3,938			3,594
Amortization of intangible assets		441			700			352			441
Gain on extinguishment of debt		0			(3,352	)
Deferred income tax expense								98			—
Changes in operating assets and liabilities:
Accounts receivable		(4,611	)		(3,780	)		428			(4,611	)
Contract asset		(794	)		(20	)
Contract assets								977			(794	)
Inventory		551			3,734			(2,558	)		551
Prepaid expenses and other assets		884			426			125			884
Accrued interest		(2,182	)		36			83			(2,182	)
Accrued payroll		(2,227	)		69
Accounts payable, accrued expenses and other liabilities		199			(726	)		(436	)		(2,028	)
Net cash (used in) provided by operating activities		(6,111	)		2,735
Net cash used in operating activities								(1,628	)		(6,111	)
Cash flows from investing activities:
Purchases of property and equipment		(3,306	)		(2,112	)		(5,517	)		(3,306	)
Net cash used in investing activities		(3,306	)		(2,112	)		(5,517	)		(3,306	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of costs		(129	)		32,103
Cash portion of $16,160 reduction to debt principal and accrued exit fee		0			(10,100	)
Payment of costs for issuance of stock								(563	)		(129	)
Payment of debt principal								(922	)		—
Payment of financing costs		(80	)		(200	)		(1,416	)		(80	)
Net payments related to vesting of restricted stock units		(110	)		(462	)		(246	)		(110	)
Net cash (used in) provided by financing activities		(319	)		21,341
Net (decrease) increase in cash and cash equivalents		(9,736	)		21,964
Net cash used in financing activities								(3,147	)		(319	)
Net decrease in cash and cash equivalents								(10,292	)		(9,736	)
Cash and cash equivalents, beginning of period		25,217			23,760			14,995			25,217
Cash and cash equivalents, end of period	$	15,481		$	45,724		$	4,703		$	15,481
Supplemental disclosures of cash flow information:
Cash paid for interest	$	7,015		$	4,833		$	3,888		$	7,015
Purchases of property, plant and equipment included in accrued expenses and accounts payable		582			191			652			582
Issuance of common stock to reduce debt principal and accrued exit fees		0			6,060
Issuance of common stock to settle interest obligations		0			3,211
Deferred financing costs included in accounts payable and accrued expenses								81			—

See accompanying notes to consolidated financial statements.

SOCIETAL CDMO, INC. AND SUBSIDIARIES

Notes to consolidated financial statements

(amounts in thousands, except share and per share data)

(Unaudited)

(1) Background

Societal CDMO, Inc. (the “Company”) was incorporated in the Commonwealth of Pennsylvania on November 15, 2007 as Recro Pharma, Inc. Effective March 21, 2022, Recro Pharma, Inc changed its name to Societal CDMO, Inc. to reflect the corporate transformation that had taken place primarily as a result of its acquisition and successful integration of IriSys, LLC (“IriSys”) into the organization.. The Company is a bi-coastal contract development and manufacturing organization with capabilities spanning pre-investigational new drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus ~~in the area of~~on small molecules. With an expertise in solving complex manufacturing problems, ~~Societal CDMO~~the Company provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. ~~The Company has determined that it operates in a~~

~~single~~ ~~segment.~~Liquidity and capital resources

The Company has incurred net losses since inception, including net losses for the three and six months ended June 30, 2023, and has an accumulated deficit of $~~253,137~~273,531 as of June 30, ~~2022, which is primarily related to~~2023. As of June 30, 2023, the ~~activities of its former research~~Company’s cash and ~~development business that was spun-out in 2019.~~cash equivalents were $4,703. The Company’s future operations are highly dependent on the profitability of its development and manufacturing operations. Management concluded that substantial doubt about its ability to continue as a going concern was raised as of the date of the issuance of these financial statements. However, management concluded that actions taken to date as well as its plans alleviate the substantial doubt that was raised.

The Company’s credit agreement with Royal Bank of Canada contains certain financial and other covenants, including a minimum liquidity requirement applicable to certain quarter-ends of $4,000, and maximum leverage ratios, and includes limitations on, among other things, additional indebtedness, paying dividends in certain circumstances, acquisitions and certain investments. The credit agreement provides for certain mandatory prepayment events, including with respect to the proceeds of asset sales, extraordinary receipts, equity or debt issuances and other specified events, based on the terms of the credit agreement. Any failure to comply with the terms, covenants and conditions of the credit agreement or the debt agreements may result in an event of default under such agreements, which could have a material adverse effect on the business, financial condition and results of operations.

The pharmaceutical industry is experiencing a slowdown in clinical development activities resulting from reduced cash funding and other liquidity resources and the Company is experiencing higher rates of customer attrition and development program delays that caused management to revise its 2023 earnings and cash projections during the second quarter of 2023. As a result of these factors, management took actions to amend its debt agreements to align financial covenants and other terms of the indebtedness with its revised projections (see note 16). Absent these amendments, management would not have been able to conclude that it was probable of complying with the provisions of its debt agreements through August 14, 2024.

The Company believes that its results of operations will allow it to comply with the financial and other covenants and contractual requirements of the agreements for at least the next twelve months. The Company’s ability to comply is subject to the Company’s success in implementing certain cost control measures, reducing capital expenditures and managing working capital in order to improve its ongoing financial performance and its liquidity position.

The Company may extend and or supplement the actions it is ~~probable~~taking if it continues to experience adverse conditions described above, among others, that might impact the forecasted performance. If the Company ~~will~~is unable to achieve the results required to comply with the terms of its credit agreement in one or more quarters over the next twelve months, the Company may be ~~able~~required to ~~meet~~take specific actions in addition to those described above, including but not limited to, additional cost control measures, or alternatively, seeking an amendment or waiver from its ~~obligations as they become due~~lenders. Obtaining a waiver or an amendment is not within ~~at least one year after~~ the ~~date financial statements included herein are issued.~~Company’s control, and if unsuccessful, the lenders may exercise the rights available to them under the credit agreement.

(2) Summary of significant accounting principles

Basis of presentation and principles of consolidation

The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. In accordance with Securities and Exchange ~~Commission's~~Commission’s (“SEC”) rules for interim financial statements, certain information required by U.S. GAAP may be condensed or omitted. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year. The Company has determined that it operates in a single segment.

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022.

Use of estimates

The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.

~~Business combinations~~

The Company measures the purchase price paid for acquired companies based on fair value and allocates that purchase price to the assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from the acquired companies and expectations of future cash flows. Costs associated with business combinations are expensed as incurred and classified as selling, general and administrative expenses.

Cash and cash equivalents

Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value due to changes in interest rates.

Accounts receivable, net

Accounts receivable generally represent amounts billed for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for credit losses, if necessary. We apply judgment in assessing the ultimate realization of our receivables, and we estimate an allowance for credit losses based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. The allowance for credit losses was not material as of the balance sheet dates presented.

Inventory

Inventory is stated at the lower of cost or net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Items are issued out of inventory using the first-in, first-out method.

Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.

Property, plant and equipment, net

Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture, office and computer equipment; sixto ten years for manufacturing equipment; 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. The Company reviews the carrying value of property, plant and equipment for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of individual assets or asset groups may not be recoverable.

The Company considers assets to be held for sale when (i) management commits to a plan to sell the asset; (ii) the asset is available for immediate sale in its present condition; (iii) the asset is actively being marketed for sale at a price that is reasonable given the estimate of current market value; and (iv) the sale is probable and will be completed within one year. Upon designation of an asset as held for sale, the Company records the asset’s value at the lower of its carrying value plus selling costs or its estimated net realizable value.

Goodwill and intangible assets

Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company in a business combination. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist.

The impairment analysis for goodwill consists of an optional qualitative assessment potentially followed by a quantitative analysis. If the Company determines that the carrying value of its reporting unit exceeds its fair value, an impairment charge is recorded for the excess.

The Company performs its annual goodwill impairment test as of November 30th, or whenever an event or change in circumstance occurs that would require reassessment of the impairment of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance, actual and anticipated changes in industry and market conditions, and competitive environments. As a result of the most recent annual goodwill impairment test, the Company determined that there was no impairment of goodwill.

Definite-lived intangible assets are amortized on a straight-line basis over their estimated useful ~~lives.~~life. The Company is required to review the carrying value of definite-lived intangible assets for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable.

Contingencies

The ~~Company's~~Company’s business exposes it to various contingencies including compliance with regulations, legal exposures and other matters. Loss contingencies are reflected in the financial statements based on ~~management's~~management’s assessments of their expected outcome or resolution:

•

They are recognized as liabilities on the balance sheet if the potential loss is probable and the amount can be reasonably estimated.

•

They are disclosed if the potential loss is material and considered at least reasonably possible.

Significant judgment is required to determine probability and whether the amount can be reasonably estimated. Due to uncertainties related to these matters, accruals are based only on the information available at the time. As additional information becomes available, the Company reassesses potential liabilities and may revise previous estimates.

Revenue recognition

The Company generates revenues from manufacturing, ~~packaging, research~~profit-sharing and development ~~and related~~ services for multiple pharmaceutical companies.

Manufacturing

Manufacturing, packaging and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include variable consideration such as pricing and volume-based adjustments.

Profit-sharing

In addition to manufacturing and packaging revenue, certain ~~customer~~customers who use our technologies are subject to agreements ~~may have~~that provide us intellectual property sales-based profit-sharing and/or royalties consideration, collectively referred to as profit-sharing, computed on the net product sales of the commercial partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. ~~For~~The Company has determined that, in its arrangements, ~~that include sales-based profit-sharing where~~ the license for intellectual property is ~~deemed to be~~not the predominant item to which the profit-sharing relates, the Company recognizes revenue when the related sales occur by the commercial partner. For arrangements that include sales-based profit-sharing where the license for intellectual property is not deemed to be the predominant item to which the profit-sharing relates,so the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by the Company’s commercial partners, which are outside of the Company’s control. Factors causing price adjustments by the Company’s commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing.

~~Research and development~~Development

~~Research and development~~Development revenue includes services associated with formulation, process development, clinical ~~trials~~trial materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms.

In contracts that specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within the Company’s control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received.

In contracts that require revenue recognition over time, the Company utilizes input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications, and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by the Company’s services and can make changes to its process or specifications upon request.

Contract assets represent revenue recognized for performance obligations completed or in process before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. Contract liabilities represent payments received from customers prior to the completion of associated performance obligations.

Concentration of credit risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity.

The Company’s accounts receivable balances are primarily concentrated among 3three ~~customers.~~customers, with balances in the aggregate accounting for 78% of the balance as of June 30, 2023. If any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition.

The Company is dependent on its relationships with a small number of commercial partners. The ~~Company's~~ 3Company’s three largest customers generated 66% and 76% of revenues for the three months ended June 30, 2023 and 2022, respectively, and 75% and 72% of its revenues for the ~~three and~~ six months ended June 30, 2023 and 2022, respectively.

Stock-based compensation expense

The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur.

Determining the appropriate fair value of stock options requires the use of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards.

The expected life of stock options was estimated using the “simplified method,” which is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option.

Upon exercise of stock options or vesting of restricted stock units, the holder may elect to cover tax withholdings by forfeiting shares of an equivalent value. In such cases, the Company issues net new shares to the holder, pays the tax withholding on behalf of the participant and presents the payment similar to a capital distribution: a reduction to additional paid-in-capital and a financing cash outflow in the consolidated financial statements.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. ~~A valuation allowance is recorded to~~

In assessing the ~~extent~~realizability of net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. A full valuation allowance was recorded as of June 30, ~~2022~~2023 and December 31, ~~2021.~~2022.

Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.

Leases

The Company determines under U.S. GAAP if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Options to extend the lease are included in the lease term if the options are reasonably certain to be exercised. Operating lease expense is recognized on a straight-line basis over the lease term.

8In a sale-leaseback transaction, the Company determines if it relinquished control of the assets to the buyer-lessor. If control is not relinquished, it does not derecognize the asset and does not apply the lease accounting model.

Operating lease balances are presented as separate captions on the balance sheets. Finance lease assets are included in property, plant and equipment. Finance lease liabilities are included in ~~debt.~~other liabilities.

Income or loss per share

Basic income or loss per share is determined by dividing net income or loss (the numerator) by the weighted average common shares outstanding during the period (the denominator).

To calculate diluted income or loss per share, the numerator and denominator are adjusted to eliminate the income or loss and the dilutive effects on shares, respectively, caused by outstanding common stock options, warrants and unvested restricted stock units, using the treasury stock method, if the inclusion of such instruments would be dilutive.

For the three months ended June 30, 2021, the Company reported net income. The calculation of net income used to determine basic and diluted per share results in the period ended June 30, 2021, is consistent with how net income is calculated in the period ended June 30, 2022, however, the calculation of we~~ighted average shares outstanding used to determine basic and diluted per share results differs. The following table reconciles that difference for the period ended June 30, 2021:~~


~~Weighted average shares outstanding, basic~~	9	~~39,018,730~~
~~Dilutive impact of:~~
~~Restricted stock units~~		~~218,253~~
~~Stock options~~		~~4,024~~
~~Warrants~~		~~111,047~~
~~Weighted average shares outstanding, diluted~~		~~39,352,054~~

For all ~~other~~ periods presented, the Company incurred a net loss. In periods of net loss, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share.

The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share:


	Three months ended June 30,				Six months ended June 30,				Three months ended June 30,				Six months ended June 30,
	2022		2021		2022		2021		2023		2022		2023		2022
Restricted stock units		1,576,166		540,942		1,514,461		456,344		3,367,297		1,576,166		2,883,887		1,514,461
Stock options		8,279,256		4,465,348		7,383,008		4,337,299		7,523,524		8,279,256		7,418,326		7,383,008
Warrants		348,664		348,664		348,664		348,664		402,126		348,664		402,126		348,664

Amounts in the table above reflect the common stock equivalents of the noted instruments.

~~Recent accounting pronouncements~~

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). This ASU provides temporary optional expedients and exceptions to the guidance on contract modifications and hedge accounting to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate and other interbank offered rates to alternative reference rates. In January 2021, the FASB issued ASU 2021-01, which refines the scope of Topic 848 and clarifies some of its guidance as part of the FASB’s monitoring of global reference rate activities. The new guidance was effective upon issuance, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.

(3) Inventory

The following table presents the components of inventory:


	June 30, 2022		December 31, 2021		June 30, 2023		December 31, 2022
Raw materials	$	4,004	$	3,038	$	6,199	$	4,318
Work in process		1,057		3,363		2,741		3,689
Finished goods		3,305		2,516		3,919		2,294
Inventory	$	8,366	$	8,917	$	12,859	$	10,301

(4)~~Property, plant and equipment, net~~

~~The following table presents the components of~~ ~~property, plant and equipment:~~

June 30, 2022

December 31, 2021

Land
$
3,263

$
3,263

Building and improvements

22,936

22,717

Furniture, office and computer equipment

6,282

6,213

Manufacturing equipment

51,026

49,687

Construction in progress

8,072

6,856

Property, plant and equipment, gross

91,579

88,736

Less: accumulated depreciation

(40,622
)

(37,028
)
Property, plant and equipment, net
$
50,957

$
51,708

~~Interest expense capitalized to construction in progress was $294~~ ~~and $~~65 ~~for the three months ended June 30, 2022 and 2021, respectively, and $563~~ ~~and $~~65 ~~for the six months ended June 30, 2022 and 2021, respectively.~~

~~(5)~~ Intangible assets, net

The following table presents the components of other intangible assets:


	June 30, 2022						December 31, 2021						June 30, 2023						December 31, 2022
	Gross value		Accumulated amortization		Carrying value		Gross value		Accumulated amortization		Carrying value		Gross value		Accumulated amortization		Carrying value		Gross value		Accumulated amortization		Carrying value
Customer relationships	$	18,900	$	15,928	$	2,972	$	18,900	$	15,685	$	3,215	$	18,900	$	16,431	$	2,469	$	18,900	$	16,188	$	2,712
Backlog		460		168		292		460		73		387		460		353		107		460		261		199
Trademarks and tradenames		310		182		128		310		79		231		310		310		—		310		293		17
Total	$	19,670	$	16,278	$	3,392	$	19,670	$	15,837	$	3,833	$	19,670	$	17,094	$	2,576	$	19,670	$	16,742	$	2,928

The following table presents estimated future amortization of other intangible assets:


Twelve months ending June 30,
2023	$	804
2024		588	$	593
2025		486		486
2026		486		486
2027		486		486
2028				486
Thereafter		542		39
Total	$	3,392	$	2,576

(5)Property, plant and equipment, net

The following table presents the components of property, plant and equipment:


	June 30, 2023			December 31, 2022
Land	$	604		$	604
Building and improvements		22,867			22,751
Furniture, office and computer equipment		6,789			6,388
Manufacturing equipment		63,846			58,039
Construction in process		5,485			7,024
Property, plant and equipment, gross		99,591			94,806
Less: accumulated depreciation		(48,379	)		(44,441	)
Property, plant and equipment, net	$	51,212		$	50,365

Interest expense capitalized to construction in process was $59 and $294 for the three months ended June 30, 2023 and 2022, respectively, and $266 and $563 for the six months ended June 30, 2023 and 2022, respectively.

The Company is party to a sale and purchase agreement to sell approximately 121 acres of land adjacent to its Gainesville, Georgia manufacturing campus for expected proceeds of $9,075. The cost of the land has been removed from property, plant and equipment, and together with cumulative closing costs of $143 through June 30, 2023, is currently presented as a held-for-sale asset of $2,802 within prepaid expenses and other current assets. The completion of the land sale is subject to customary closing conditions for transactions of this type, including completion of title and environmental due diligence and receipt of certain zoning approvals and permits, which remained to be satisfied at June 30, 2023.

(6) Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

June 30, 2022

December 31, 2021

Payroll and related costs
$
3,490

$
5,717

Current portion of contract liabilities (see note 10)

2,216

2,308

Property, plant and equipment

375

663

Professional and consulting fees

476

552

Accrued interest

323

2,505

Other

904

811

Total
$
7,784

$
12,556


	June 30, 2023		December 31, 2022
Payroll and related costs	$	2,902	$	4,276
Contract liabilities (see note 11)		1,281		2,211
Accrued transaction costs		781		3,653
Property, plant and equipment		162		934
Other		2,011		1,612
Total	$	7,137	$	12,686

10Accrued transaction costs include costs incurred related to the refinancing completed in December 2022 which included the sale and subsequent leaseback of the Company’s commercial manufacturing campus located in Gainesville, Georgia (see note 9), the issuance of common and preferred stock, a borrowing of $36,900 under a new term loan with Royal Bank of Canada (see note 8) and a one-time cash transaction bonus to certain executive officers and employees.

(7) Commitments and contingencies

Litigation

The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. ~~Except as disclosed below, the~~The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations.

On May 31, 2018, a securities class action lawsuit (the “Securities Litigation”) was filed against the Company and certain of its officers and directors (collectively, the “Defendants”) in the U.S. District Court for the Eastern District of Pennsylvania (the “Court”) (Case No. 2:18-cv-02279-MMB) that purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning the New Drug Application (“NDA”) for IV meloxicam. The complaint seeks unspecified damages, interest, attorneys’ fees and other costs. On December 10, 2018, the lead plaintiff filed an amended complaint that asserted the same claims and sought the same relief but included new allegations and named additional officers as defendants. On February 8, 2019, the Company filed a motion to dismiss the amended complaint in its entirety, which the lead plaintiff opposed on April 9, 2019. On May 9, 2019, the Company filed its response and briefing was completed on the motion to dismiss. In response to questions from the Court, the parties submitted supplemental briefs regarding the motion to dismiss the amended complaint during the fall of 2019. On February 18, 2020, the motion to dismiss was granted by the Court without prejudice. On April 25, 2020, the plaintiff filed a second amended complaint. The Company filed a motion to dismiss the second amended complaint on June 18, 2020. The plaintiff filed an opposition to the Company’s motion to dismiss on August 17, 2020. On September 16, 2020, the Company filed a reply in support of its motion to dismiss. On March 1, 2021, the Court denied the Company’s second motion to dismiss. On June 21, 2021, the Defendants filed an answer and affirmative defenses to the second amended complaint. Since then, the parties have been engaged in discovery, which must conclude by April 29, 2022. On September 30, 2021, the plaintiff filed a motion for class certification and appointment of class representative. The Company filed an opposition to the plaintiff’s motion on November 30, 2021. On January 6, 2022, the plaintiff filed a reply in support of the motion for class certification. On March 24, 2022, the plaintiff informed the Court that the parties had reached an agreement-in-principle to settle the Securities Litigation and requested that the Court stay all deadlines. On May 10, 2022, the plaintiff filed an unopposed motion for preliminary approval of the class action settlement. The Court entered an order preliminarily approving the settlement and providing for notice on May 12, 2022. A hearing for the final approval of the settlement is set for October 26, 2022.

In connection with the separation of the Company's former acute care research and development business into a new standalone entity named Baudax Bio, Inc. (“Baudax Bio”), Baudax Bio accepted assignment by the Company of all of its obligations in connection with the Securities Litigation and agreed to indemnify it for all liabilities related to the Securities Litigation.

On July 2, 2022, a product liability lawsuit was filed against the Company and various other defendants in the State Court of Cobb County, Georgia that claimed injuries and damages caused by Plaintiff Jakob Cuble’s alleged ingestion of, ~~inter alia,~~among other things, Focalin XR. The complaint ~~seeks~~sought compensatory and punitive damages. On ~~July 7, 2022, and prior to~~April 14, 2023, Plaintiff's counsel withdrew the Company’s being served with the complaint, a co-defendant removed the matter to the United States District Court for the Northern District of Georgia, Atlanta Division. The Company filed its responsive pleading on August 2, 2022.case.

Purchase commitments

As of June 30, ~~2022,~~2023, the Company had outstanding cancelable and non-cancelable purchase commitments in the aggregate amount of $~~10,580~~7,992 related to inventory, capital expenditures and other goods and services.

Employment agreements and certain other contingencies

The Company has entered into employment agreements with each of its ~~named~~ executive officers that provide for, among other things, severance commitments of up to $~~1,303~~1,393 should the Company terminate the ~~named~~ executive officers for convenience or if certain events occur following a change in control. In addition, the Company is subject to other contingencies of up to $~~3,772~~4,597 in the aggregate if certain events occur following a change in control.

(8) Debt

The following table presents the components and classification of debt:


	June 30, 2022			December 31, 2021			June 30, 2023			December 31, 2022
Debt principal:
Terms loans under Credit Agreement	$	100,000		$	100,000
Term loan under Credit Agreement							$	35,978		$	36,900
Note with former equity holder of IriSys		6,117			6,117			4,078			4,078
Other		339			339			339			339
Debt principal		106,456			106,456			40,395			41,317
Debt adjustments:
Unamortized deferred issuance costs		(6,770	)		(8,896	)		(2,076	)		(2,476	)
Exit fee accretion		751			669
Unamortized original discount		(452	)		(694	)		(161	)		(297	)
Carrying value of debt	$	99,985		$	97,535		$	38,158		$	38,544

Current portion of related party debt	$	2,039		$	2,039
Current portion of debt							$	7,148		$	7,577
Debt, net of current portion		94,360			92,127			31,010			30,967
Related party debt, net of current portion		3,586			3,369
Carrying value of debt	$	99,985		$	97,535		$	38,158		$	38,544

The following table presents the future maturity of debt principal:


Twelve months ending June 30,
2023	$	2,039
2024		102,041	$	7,148
2025		2,068		5,299
2026		35		27,675
2027		42		42
2028				51
Thereafter		231		180
Total debt principal	$	106,456	$	40,395

Term ~~loans~~loan under Credit Agreement

See note 16 for information about an amendment to the Credit Agreement that occurred subsequent to June 30, 2023.

The Company is currently party to a credit agreement ~~(the~~(as amended from time to time, the “Credit Agreement”) with ~~Athyrium Opportunities III Acquisition LP (“Athyrium”).~~Royal Bank of Canada. The Credit Agreement has been fully drawn in the form of a term loan of $~~48,000~~36,900 ~~of term A loans~~. The outstanding principal amount will be repaid in quarterly amounts totaling $2,306, $3,229 and $~~52,000~~923 during the twelve months ending June 30, 2024, 2025 and 2026, respectively. The final payment of ~~term B loans,~~ all ~~of which mature~~remaining outstanding principal is due on December ~~31, 2023~~16, 2025..

~~The term loans under~~Subject to certain exceptions, the ~~Credit Agreement bear~~Company is required to make mandatory prepayments with the cash proceeds received in respect of asset sales, certain equity sales, extraordinary receipts, debt issuances, upon a ~~rate~~change of ~~interest equal~~control and specified other events. Additionally, the Company is obligated by December 14, 2023 to complete the ~~three-month LIBOR rate, with a~~ 1~~% floor, plus~~ ~~8.25% per annum~~sale of certain real property adjacent to its Gainesville, Georgia manufacturing campus (see note 5). ~~The term loans require~~If that property is not sold by December 14, 2023, the Company will be required to pay a fee of $1369~~% exit fee on all repayments. At~~ and increase each of its quarterly principal payments by $231 until that property is sold and any mandatory prepayment is made. Because the Company concluded that the sale of the property is probable as of June 30, ~~2022, the aggregate exit fee payable was~~2023, an additional $~~1,000~~2,802~~, and the cumulative exit fee accreted was $751. The exit fees are being accreted to~~ of debt principal has been presented as current, representing the carrying ~~amount~~value of the ~~debt using the effective interest method over the term of the loan. In addition,~~ ~~if the Company makes any prepayments prior to maturity, the Company would be subject to prepayment premiums on the term B loans, as a percentage of the amount repaid, of~~ ~~2.5~~%.current asset held for sale.

The Credit Agreement ~~contains~~also includes certain ~~usual and customary affirmative and negative covenants, as well as~~ financial covenants that the Company will need to satisfy on a ~~monthly and~~ quarterly basis, including maintaining a permitted net leverage ratio (which is the Company’s indebtedness under the Credit Agreement, net of cash and cash equivalents, divided by EBITDA, each as defined in the Credit Agreement) and liquidity amount.basis. As of June 30, ~~2022,~~2023, the Company was in compliance with its covenants under the Credit Agreement.

In connection with the Credit Agreement, the Company ~~issued warrants to each of Athyrium and its affiliate, Athyrium Opportunities II Acquisition LP (“Athyrium II”), to purchase an aggregate of~~ ~~348,664~~ ~~shares of the Company’s common stock with an exercise price of $1.73~~ ~~per share. See note 9 for additional information. The warrants are exercisable through~~ ~~November 17, 2024~~.

~~In connection with the Credit Agreement and amendments made to it over the years, the Company~~ has paid financing ~~costs, has incurred costs to record and subsequently to adjust the value of the warrants described above and has been accreting the exit fee described above.~~costs. These costs are being recognized in interest expense using the effective interest method over the term of the Credit Agreement, resulting in non-cash interest expense of $~~1,151~~233 and $~~1,618~~469 for the three ~~months ended June 30, 2022~~ and ~~2021, respectively, and $2,288~~ ~~and $3,080~~ ~~for the~~ six months ended June 30, ~~2022 and 2021,~~2023, respectively.

The Credit Agreement bears interest at a floating rate equal to the three-month term Secured Overnight Financing Rate, or SOFR, with an initial floor of 1.00%, plus an applicable margin that is equal to 4.50% per annum for the first year, 5.00% for the second year and 5.50% for the third year, with quarterly interest payments due until maturity.At June 30, ~~2022,~~2023, the overall effective interest rate, including cash paid for interest and non-cash interest expense, was ~~13.8~~12.4%.

Historical term loans with Athyrium

The Company was previously party to a credit agreement with Athyrium Opportunities III Acquisition LP (“Athyrium Credit Agreement”). The Athyrium Credit Agreement included $100,000 of term loans at an interest rate equal to the three-month LIBOR rate plus 8.25% per annum.

During the term of Athyrium Credit Agreement, the Company paid financing costs and accreted an exit fee. These costs were recognized in interest expense using the effective interest method, resulting in non-cash interest expense of $1,151 and $1,618 for the three and six months ended June 30, 2022, respectively. The Company repaid the term loans in full using the proceeds from the new Credit Agreement, the sale-leaseback transaction (see note 9) and the issuance of preferred and common stock (see note 10) in December 2022.

Note with former equity holder of IriSys

See note 16 for information about an amendment to the Note that occurred subsequent to June 30, 2023.

In connection with the acquisition of IriSys, LLC (“IriSys”), the Company issued a subordinated promissory note to a former equity holder of IriSys in the aggregate principal amount of $6,117 (the “Note”). The Note is unsecured, has a three-year term, and bears interest at a rate of 6% per annum. The Note must be repaid in three equal ~~annual~~ installments through its maturity date, August 13, 2024. The Note may be prepaid in whole or in part at any time prior to the maturity date. The Note is expressly subordinated in right of payment and priority to the term ~~loans~~loan under the Credit ~~Agreement with Athyrium.~~Agreement.

The Note was initially recognized at fair value as part of the consideration paid for the acquisition of IriSys, resulting in an original discount recognized of $877 that is being recognized as interest expense using the effective interest method over the term of the Note. At June 30, ~~2022,~~2023, the overall effective interest rate, including the amortization of the original discount, was 13.0%.

~~Since~~(9) Other liabilities

At June 30, 2023, other liabilities include a sale-leaseback liability of $38,589 and other liabilities of $1,131.

Sale-leaseback liability

In December 2022, the ~~acquisition~~Company concurrently entered into sale and lease agreements related to its commercial manufacturing campus in Gainesville, Georgia. The selling price was $39,000, of ~~IriSys, we believe that~~which $1,750 was placed as a lease deposit and classified within other assets, resulting in cash proceeds to the ~~note holder has held~~Company of $37,250 in 2022. The lease is for an initial term of 20 years with four renewal options of ten years each. Rent under the lease will be payable monthly at a ~~combination~~rate of ~~direct beneficial interests~~$3,510 per year, increasing annually by 3%, except for the first year where annual base rent will increase by the change in the consumer price index, not to exceed 5%, if greater. The Company is responsible for the payment of all operating expenses, property taxes and ~~significant influence over at least 10%~~insurance for the property. Pursuant to the terms of the ~~Company's outstanding common stock. As a result,~~lease, the Company ~~has presented~~will have a purchase option every ten years and a right of first offer and a right of first refusal to purchase the ~~note holder~~property should the buyer-lessor intend to sell the property to a third party.

The Company determined that it did not relinquish control of the assets to the buyer-lessor. Therefore, the assets were not derecognized, and the selling price was recorded as a ~~related party.~~financial liability. As of June 30, 2023, the carrying value of the liability was $38,589, which is net of $838 of unamortized deferred financing costs. The Company ~~has accrued~~will recognize interest expense at an approximately 11% imputed rate of $interest over a term of ~~323~~20 years that includes the amortization of the deferred financing costs over the term of the lease. The gross liability balance is scheduled to increase through ~~June 30, 2022 that~~2034, at which point it will ~~become payable to~~decrease through the ~~former equity holder~~end of ~~IriSys~~lease term on ~~August 13, 2022.~~December 31, 2042.

~~Other~~13

~~In connection with the acquisition of IriSys, the Company assumed a loan with a principal amount of $339~~.

~~(9)~~(10) Shareholders’ equity or deficit

~~Capital raises~~

~~The following table presents the Company’s capital raises since its initial public offering in March 2014:~~Common stock

On May 17, 2023, the Company's shareholders approved an amendment to the articles of incorporation to increase the number of authorized shares of common stock from

Date or period

Shares of common stock issued

Gross proceeds

Offering expenses

Net proceeds

Initial public offering
March 12, 2014

4,312,500

$
34,500

$
(4,244
)

$
30,256

Private placement
July 7, 2015

1,379,311

16,000

(1,188
)

14,812

Underwritten public offering
August 19, 2016

1,986,666

14,900

(1,533
)

13,367

Underwritten public offering
December 16, 2016

6,670,000

40,020

(3,132
)

36,888

2018 common stock purchase agreement with Aspire Capital
Year ended December 31, 2018

1,950,000

16,999

—

16,999

2019 common stock purchase agreement with Aspire Capital
Fourth quarter 2020

4,690,972

11,172

(78
)

11,094

Share issuance agreement for amendment 5 to Credit Agreement
February 2021

2,202,420

9,338

(20
)

9,318

Underwritten public offering
May 12, 2021

15,333,332

34,500

(2,397
)

32,103

Issuance of shares for IriSys acquisition
February 2022

9,302,718

20,931

(619
)

20,312

95,000,000

~~Shares issued~~ to 185,000,000.

~~As part of the consideration paid for the acquisition of IriSys,~~Convertible preferred stock

In December 2022, the Company issued ~~9,302,718~~450,000 shares of ~~its~~Series A Convertible Preferred Stock for proceeds of $11.00 per share. Each share was convertible into ten shares of common stock ~~on February 23, 2022.~~

~~Aspire common stock purchase agreement~~

The Company is currently party to an amended common stock purchase agreement with Aspire Capital Fund LLC (“Aspire Capital”) originally entered into during 2019, and most recently amended in February 2021 (as amended, the “2019 Common Stock Purchase Agreement”). The 2019 Common Stock Purchase Agreement provides that,automatically upon ~~the terms and subject to the conditions and limitations set forth in the agreement, Aspire Capital is committed to purchase, at~~approval by the Company’s ~~sole election, up~~shareholders to ~~an aggregate value~~increase the number of $~~41,172~~ inauthorized shares of common stock. As of June 30, ~~2022, there is availability to issue up to $~~2023, ~~30,000~~no preferred stock was issued or ~~6,199,299~~ ~~shares of common stock under the 2019 Common Stock Purchase Agreement.~~outstanding.

Warrants

See note 16 for information about warrants that were issued subsequent to June 30, 2023.

At June 30, ~~2022,~~2023, warrants to purchase ~~348,664~~402,126 shares of common stock were outstanding. The warrants were originally issued to Athyrium in connection with the Athyrium Credit Agreement, are ~~held by Athyrium,~~ equity-classified, exercisable at $~~1.73~~1.50 per share and expire in November 2024. ~~See note 8 for additional details.~~

~~(10)~~(11) Revenue recognition

The following table presents changes in contract assets and liabilities:

Contract assets

Contract liabilities

Balance at December 31, 2021
$
8,565

$
2,308

Changes to the beginning balance of contract assets arising from:

Reclassification to receivables as a result of rights to consideration becoming unconditional

(10,518
)

—

Reduction to offset within net contract asset due to recognition of revenue

676

—

Changes in estimate

1,512

—

Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates

9,124

—

Changes to contract liabilities:

Amounts billed in advance of contract performance

—

4,275

Revenue recognized

—

(4,367
)
Balance at June 30, 2022
$
9,359

$
2,216


	Contract assets			Contract liabilities
Balance at December 31, 2022	$	8,724		$	(2,211	)
Changes to the beginning balance arising from:
Reclassification to receivables as the result of rights to consideration becoming unconditional		(9,625	)		—
Reclassification to revenue as the result of performance obligations satisfied		688			1,579
Changes in estimate		1,579			—
Net change to contract balance recognized since beginning of period due to recognition of revenue, amounts billed and changes in estimate		6,381			(649	)
Balance at June 30, 2023	$	7,747		$	(1,281	)

Contract assets and contract liabilities are reported at the contract level. Contracts with multiple performance obligation are reported as a net contract asset or contract liability on the consolidated balance sheet. The reclassification to revenue appearing in the contract assets column results from the recognition of revenue on contract liabilities that are presented as a net contract asset at the beginning of the year.

The following table disaggregates revenue by timing of revenue recognition:


	Three months ended June 30,				Six months ended June 30,				Three months ended June 30,				Six months ended June 30,
	2022		2021		2022		2021		2023		2022		2023		2022
Point in time	$	19,406	$	16,439	$	36,286	$	31,586	$	16,368	$	19,406	$	33,181	$	36,286
Over time		3,746		1,578		8,060		3,234		5,431		3,746		10,145		8,060
Total	$	23,152	$	18,017	$	44,346	$	34,820	$	21,799	$	23,152	$	43,326	$	44,346

The Company’s payment terms for manufacturing revenue and development services are typically 30 to 45 days. Profit-sharing revenue is recorded to accounts receivable in the quarter that the product is sold by the commercial partner upon reporting from the commercial partner and payment terms are generally 45 days after quarter end.

~~(11)~~(12) Stock-based compensation

In October 2013, the Company established an equity incentive plan that has been subsequently amended and restated to become the 2018 Amended and Restated Equity Incentive Plan (the “A&R Plan”). At June 30, ~~2022,~~2023, a total of ~~226,745~~299,809 shares were available for future grants under the A&R Plan. On December 1st of each year, pursuant to an “evergreen” provision of the A&R Plan, the number of shares available under the A&R Plan may be increased by the board of directors by an amount equal to 5% of the outstanding common stock on December 1st of that year.

Stock options

Stock options are exercisable generally for a period of 10ten years from the date of grant and generally vest over four years.

The following table presents information about the fair value of stock options granted:


	Six months ended June 30,				Six months ended June 30,
	2022		2021		2023		2022
Weighted average grant date fair value	$	1.02	$	1.90	$	0.96	$	1.02
Assumptions used to determine fair value:
Range of expected option life	5.5 - 6.0 years		5.5 - 6.0 years		5.5 - 6.0 years		5.5 - 6.0 years
Expected volatility	79 - 81%		79 - 81%		79 - 83%		79 - 81%
Risk-free interest rate	1.5 - 3.0%		0.7 - 1.2%		3.5 - 4.1%		1.5 - 3.0%
Expected dividend yield		0		0		—		—

No options were exercised in the six months ended June 30, 2023. The intrinsic value of options exercised was negligible in the six months ended June 30, ~~2022, and~~ 0 ~~stock options were exercised in the six months ended June 30, 2021.~~2022.

The following table presents information about stock option balances and activity:


	Number of shares			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life	Number of shares			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life
Balance, December 31, 2021		5,267,567		$	6.47			5.7 years
Balance, December 31, 2022										8,050,337		$	3.89
Granted		3,833,853			1.49					1,813,879			1.35
Exercised		(220	)		1.71
Forfeited or expired		(392,414	)		4.61					(1,470,052	)		7.13
Balance, June 30, 2022		8,708,786			4.36	$	0	7.2 years
Balance, June 30, 2023										8,394,164			2.77	$	10	7.7 years
Exercisable		4,087,743			6.96		0	4.3 years		4,291,287			3.81		—	6.5 years

Included in the table above are ~~1,104,677~~1,043,949 options outstanding as of June 30, ~~2022~~2023 that were granted outside the A&R Plan. The grants were made pursuant to the inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

Restricted stock units

Restricted stock units (“RSUs”) vest over six months to four years depending on the purpose of the award and sometimes include performance conditions in addition to service conditions. The fair value of RSUs on the date of grant is measured as the closing price of the ~~Company's~~Company’s common stock on that date. The weighted average grant-date fair value of RSUs awarded to employees was $1.30 in the six months ended June 30, 2023 and $1.32 in the six months ended June 30, ~~2022 and $3.49~~ ~~in the six months ended June 30, 2021.~~2022. The fair value of RSUs vested was $1,183 and $719 in the six months ended June 30, 2023 and 2022, ~~and $1,537~~ ~~in the six months ended June 30, 2021.~~respectively.

The following table presents information about recent RSU activity:


	Number of shares			Weighted average grant date fair value		Number of shares			Weighted average grant date fair value
Balance, December 31, 2021		990,065		$	3.63
Balance, December 31, 2022							2,061,866		$	1.71
Granted		1,552,590			1.32		2,640,762			1.30
Vested		(461,735	)		3.78		(1,160,599	)		1.53
Forfeited		(46,133	)		2.65		(45,049	)		2.37
Balance, June 30, 2022		2,034,787			1.86
Balance, June 30, 2023							3,496,980			2.69

Included in the table above are ~~110,259~~73,506 time-based RSUs outstanding at June 30, ~~2022~~2023 that were granted outside of the A&R Plan. The grants were made pursuant to the inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

Other information

The following table presents the classification of stock-based compensation expense:


	Three months ended June 30,				Six months ended June 30,				Three months ended June 30,				Six months ended June 30,
	2022		2021		2022		2021		2023		2022		2023		2022
Cost of sales	$	525	$	983	$	916	$	2,375	$	588	$	525	$	995	$	916
Selling, general and administrative expenses		883		946		1,971		2,687		1,005		883		1,642		1,971
Total	$	1,408	$	1,929	$	2,887	$	5,062	$	1,593	$	1,408	$	2,637	$	2,887

As of June 30, ~~2022,~~2023, there was $~~9,721~~9,358 of unrecognized compensation expense related to unvested options and RSUs that are expected to vest and will be expensed over a weighted average period of ~~2.5~~2.6 years.

~~On June 1, 2022,~~(13) Income taxes

The tax provision for interim periods is determined using the ~~Company issued an offer to certain employee optionholders (“Eligible Employees”), subject to specified conditions, to exchange and cancel certain options which met~~estimated annual effective consolidated tax rate, based on the defined eligibility requirements (“Eligible Options”) for a new RSU grant (“New RSUs”) (collectively known as the “Exchange Offer”). Pursuant to the Exchange Offer, 130 Eligible Employees elected to exchange Eligible Options, and the Company accepted for cancellation Eligible Options to purchase an aggregatecurrent estimate of ~~668,819~~ ~~shares of common stock, representing approximately~~ 97~~% of the total shares of common stock underlying the Eligible Options. On July 1, 2022, promptly following the expiration of the Exchange Offer, the Company granted~~ ~~167,324~~ ~~New RSUs in exchange~~full-year earnings before taxes, adjusted for the ~~cancellation~~impact of ~~the tendered Eligible Options. The New RSUs will vest in two equal annual installments.~~

~~(12) Acquisition of IriSys~~discrete quarterly items.

On The provision for income taxes was $~~August 13, 2021~~39~~, the Company acquired all of the units of IriSys pursuant to a unit purchase agreement. IriSys provides contract pharmaceutical product development~~ and manufacturing services, specializing in formulation research and development and good manufacturing practices of clinical trial materials and specialty pharmaceutical products. The acquisition advances the Company’s ongoing growth strategy and leads to key synergies within business development, clinical development and commercial scale-up, as well as a strong cultural alignment and fit between the companies.$

~~The following table presents unaudited supplemental pro forma financial information~~111 for the three and six months ended June 30, ~~2021 as if~~2023, respectively. There was no provision for income taxes for the ~~IriSys acquisition had occurred on January 1, 2021:~~

Three months ended June 30,

Six months ended June 30,

2021

2021

Revenue
$
21,378

$
41,664

Net income (loss)

586

(5,697
)

three or six months ended June 30, 2022. The ~~pro forma financial information presented above has been prepared by combining~~change in effective tax rate to (1)% in the ~~Company's historical results and~~2023 period from 0% in the historical results of IriSys and adjusting those results to eliminate historical transaction costs and to reflect the effects of the acquisition as if they occurred on January 1, 2021. The effects of the acquisition on the historical pro forma financial information include additional depreciation and amortization expense from the increase of asset carrying values to fair value, the adoption of new accounting standards, additional interest expense from the issuance of the subordinated promissory note and the elimination of interest expense related to indebtedness of IriSys prior periods was due to the ~~acquisition. These results do not purport to be indicative~~utilization of all net operating loss carryforwards without limitations during 2022 in connection with the results of operations which actually would have resulted had the acquisitions occurred on the date indicated above, or that may result in the future, and do not reflect potential synergies or additional costs following the acquisition.sale-leaseback transaction (see note 9).

~~(13)~~(14) Fair value of financial instruments

The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments and certain warrants. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows:

•

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;

•

Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and

•

Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Items measured at fair value on a recurring basis

Cash equivalents of $~~10,754~~2,525 at June 30, ~~2022~~2023 and $~~15,247~~6,034 at December 31, ~~2021~~2022 consisted entirely of money market mutual funds whose fair value were determined using Level 1 measurements.

Fair value disclosures

The Company follows the disclosure provisions of FASB ASC Topic 825, “Financial Instruments” (ASC 825), for disclosure purposes for financial assets and financial liabilities that are not measured at fair value. As of June 30, ~~2022,~~2023, the financial assets and liabilities recorded on the consolidated balance sheets that are not measured at fair value on a recurring basis include accounts receivable, accounts payable and accrued expenses. The carrying values of these financial assets and liabilities approximate fair value due to their short-term nature.

The fair value of long-term debt, where a quoted market price is not available, is evaluated based on, among other factors, interest rates currently available to the Company for debt with similar terms, remaining payments and considerations of the Company’s creditworthiness. The Company determined that the recorded book value of its debt, a level 2 measurement, approximated fair value at June 30, ~~2022~~2023 due to the recent issuances ~~and amendment~~ of those instruments and taking into consideration ~~management's~~management’s current evaluation of market conditions.

~~(14)~~(15) Leases

The Company is party to 2two operating leases for development facilities in California and Georgia that end in 2031and 2025, respectively, as well as other immaterial operating leases for office space, storage and office equipment. The development facility leases each include options to extend, none of which are included in the lease terms. Short-term and variable lease costs were not material for the periods presented. The development facility leases do not provide an implicit rate, so the Company uses its incremental borrowing rate to discount the lease liabilities.

Undiscounted future lease payments for the 2two development leases, which were the only material noncancelable leases at June 30, ~~2022,~~2023, were as follows:


Twelve months ended June 30,
2023	$	1,151
2024		1,179		$	1,179
2025		1,208			1,208
2026		1,094			1,094
2027		1,019			1,112
2028					1,143
Thereafter		4,252			3,109
Total lease payments		9,903			8,845
Less imputed interest		(4,065	)		(3,371	)
Total operating lease liabilities	$	5,838		$	5,474

At June 30, ~~2022,~~2023, the weighted average remaining lease term was ~~8.2~~ 7.3years, and the weighted average discount rate was 14.1%. Total lease cost was $~~351~~321 and $~~839~~485 for the three months ended June 30, 2023 and 2022, respectively, and $801 and $973 for the six months ended June 30, 2023 and 2022, ~~respectively,~~respectively.

(16) Subsequent events

Amendment to Seller Note

In August 2023, the Company and IriSys, Inc. (the “Seller”) entered into a First Amendment to Subordinated Promissory Note (the “Note Amendment”) pursuant to which the parties agreed to defer the due date of the payment due to the Seller on August 12, 2023 of $852,039 of principal, plus accrued interest, under the Subordinated Promissory Note to the earlier of (i) June 24, 2024; and (ii) the date on which the Company completes its previously announced sale of certain land at its Gainesville, Georgia location (see note 5). In addition, the Note Amendment provides that the Company will pay up to $~~186~~1,000 ~~for~~of the deferred payment upon completion of certain financings. In consideration of Seller’s entry into the Note Amendment, the Company paid the Seller a $150 amendment fee, agreed to pay up to $50 of Seller’s legal fees in connection with the Note Amendment and issued the Seller a warrant to purchase 100,000 shares of the Company’s common stock, par value $0.01 per share at an exercise price of $1.00 with a term of three ~~and six months ended June 30, 2021, respectively.~~years.

Amendment to the RBC Credit Agreement

In August 2023, the Company amended its Credit Agreement with Royal Bank of Canada pursuant to a Second Amendment and Waiver to Credit Agreement (the “Credit Agreement Amendment”). Pursuant to the terms of the Credit Agreement Amendment: (i) the Company is obligated to make a $7,500 mandatory principal prepayment upon the sale of the Company’s real property located adjacent to its Gainesville, Georgia manufacturing campus (see note 5); (ii) effective for the fiscal quarter ending September 30, 2023 through the quarter ending March 31, 2024, the net leverage ratio is permitted to be no greater than 3.75:1.00, stepping down to 2.75:1.00 for each quarter thereafter; (iii) effective for the quarter ending September 30, 2023, the permitted fixed charge coverage ratio was decreased to 1.00:1.00, which increases to 1.05:1.00 for each quarter thereafter; (iv) the permitted quarterly minimum liquidity amount of $4,000 was extended through June 30, 2024, after which the quarterly minimum liquidity amount increases to $4,500 through September 30, 2024 and increases to $5,000 through September 30, 2025; (v) a new permitted monthly minimum liquidity amount was established applicable to all month-end dates, other than quarter-end dates, and equal to $1.5 million; and (vi) beginning with the quarter ending December 31, 2023, funded capital expenditures, as defined, cannot exceed $9,000 in the aggregate for the preceding twelve-month period. In connection with the amendment, the Company paid an amendment fee of $90.

Item 2. Management’s discussion and analysis of financial condition and results of operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and notes thereto in Part I, Item 1 of this Quarterly Report on Form 10-Q, or Quarterly Report, and the audited consolidated financial statements and notes thereto for the year ended December 31, ~~2021~~2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the SEC on March 1, ~~2022,~~2023, or Annual Report.

In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions and other factors that could cause actual results to differ materially from those made, projected or implied in the forward-looking statements. Our actual results may differ materially from those discussed below. Please see “Forward-Looking Statements” and “Risk Factors” included in Part I, Item 1A of our Annual Report for factors that could cause or contribute to such differences.

Cautionary note regarding forward-looking statements

This Quarterly Report and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report or the documents incorporated by reference herein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” “could,” “should,” “potential,” “seek,” “evaluate,” “pursue,” “continue,” “design,” “impact,” “affect,” “forecast,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.

The forward-looking statements in this Quarterly Report and the documents incorporated herein by reference include, among other things, statements about:

•

our estimates regarding expenses, future revenue, cash flow, capital requirements and timing and availability of and the need for additional financing;

•

our ability to maintain or expand our relationships, profitability and contracts with our key commercial partners, including the impact of changes in consumer demand for the products we manufacture for our commercial partners;

•

our ability to grow and diversify our business with new customers, including our ability to meet desired project outcomes with development customers, and the potential loss of development customers if they do not receive adequate funding or if their products do not obtain U.S. Food and Drug Administration, or FDA, approval;

•

~~the risk that failure~~our ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market (“Nasdaq”), may result in receipt of a Nasdaq delisting notice; if upon receipt of a delisting notice, we fail to regain compliance within any allowed grace period or other process providedoperate under the ~~Nasdaq listing requirements,~~lending covenants under our ~~common stock may be delisted~~credit agreement and ~~the value of our common stock may decrease;~~to pay required interest and principal amortization payments when due;

•

the extent to which ~~the ongoing COVID-19 pandemic~~health epidemics and other outbreaks of communicable diseases, ~~continue to~~inflation, geopolitical turmoil, social unrest, global instability, including political instability and any resulting sanctions, terrorism, or other acts of war, supply chain disruptions, trade restrictions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities may disrupt our business operations ~~and~~or our financial condition or the financial condition of our customers and suppliers, including our ability to initiate and continue relationships with manufacturers and third-party logistics ~~providers given recent supply chain challenges;~~

•

the extent to which inflation, global instability, including political instability, such as a deterioration in the relationship between the US and China or escalation in conflict between Russia and Ukraine, including any additional resulting sanctions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities in, for example, Russia, may disrupt our business operations or our financial condition or the financial condition of our customers and suppliers;

•

our ability to operate under increased leverage and associated lending covenants; to pay existing required interest and principal amortization payments when due; and/or to obtain acceptable refinancing alternatives;providers;

•

the performance of third-party suppliers upon which we depend for Active Pharmaceutical Ingredients, or APIs, various other direct and indirect materials, and other third parties involved with maintenance of our facilities and equipment;

•

our ability to maintain and defend our intellectual property rights against third-parties;

•

pharmaceutical industry market forces that may impact our commercial customers’ success and continued demand for the products we produce for those customers;

•

our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers, including as a result of applicable state and federal vaccine mandates;

•

our ability to maintain the listing of our common stock on the Nasdaq Capital Market;

•

our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP, compliance and U.S. Drug Enforcement Agency, or DEA, compliance and other relevant regulatory authorities applicable to our business; and

•

our ability to realize the expected benefits of the IriSys, LLC, or IriSys, acquisition.

We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report, particularly under “Item 1A. Risk Factors,” that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make. You should read this Quarterly Report and the documents that we incorporate by reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements.

Solely for convenience, tradenames referred to in this Quarterly Report appear without the ® symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these tradenames. All trademarks, service marks and tradenames included or incorporated by reference in this Quarterly Report are the property of their respective owners.

Overview

Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization, or CDMO, with capabilities spanning pre-investigational new drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus ~~in the area of~~on small molecules. With an expertise in solving complex ~~formulation and~~ manufacturing problems, ~~we are~~Societal is a leading CDMO providing development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. In addition to our experience in handling DEA-controlled substances and developing and manufacturing ~~advanced~~modified-release dosage forms, ~~we have~~Societal has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our ~~best-in-class~~state-of-the-art facilities that, in the aggregate, total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

We currently manufacture the following key products with our key commercial partners: Ritalin LA®, Focalin XR®, Verelan PM®, Verelan SR®, Verapamil PM, Verapamil SR and Donnatal liquids and ~~tablets and Scot-Tussin cough and cold liquids, as well as supporting~~tablets. We also support numerous development stage products. During the first quarter of 2023, the FDA approved the Company as a manufacturer of a commercial tablet product. This FDA approval represents the first commercial tablet that Societal CDMO has been approved to manufacture, and the Company began commercial manufacturing of the product at its Gainesville, Georgia facilities in the middle of 2023.

~~Effective March 21,~~Our manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle high potent compounds and controlled substances, liposomes and nano/microparticles, topicals and oral liquids. In September 2022, Societal announced a new state-of-the-art, aseptic fill/finish and lyophilization suite in our San Diego facility to further our goal of offering end-to-end solutions to our clients. In addition to providing manufacturing capabilities, we ~~changed~~offer our ~~name~~customers clinical trial support including over-encapsulation, comparator sourcing, packaging, labeling, storage and distribution. We have a bi-coastal footprint from which to ~~Societal CDMO, Inc.~~better serve clients within the U.S., as well as globally. In a typical collaboration between us and our commercial partners, we continue to ~~reflect the corporate transformation that has taken place primarily as a result~~work with our partners to develop product candidates or new formulations of ~~our acquisition~~existing product candidates. We also typically exclusively manufacture and ~~successful integration~~supply clinical and commercial supplies of ~~IriSys into the organization.~~these proprietary products and product candidates.

We use cash flow generated by our business primarily to fund the growth of our CDMO business and to make payments under our credit facility. We believe our business will continue to contribute cash to fund our growth, to make payments under our credit facility and for other general corporate purposes.

Global economic and supply conditions

Global economic conditions, logistics and supply chain issues continue to present obstacles to our ~~business despite having endured other challenges related to the COVID-19 pandemic during 2021.~~business.

We rely on third-party manufacturers to supply our manufacturing components, supplies and related materials, which in some instances are supplied from a single source. Prolonged disruptions in the supply of any of our third-party materials, difficulty implementing new sources of supply or significant price increases could have an adverse effect on our results. ~~While the impact of COVID-19 has lessened in many ways, we~~We are experiencing a higher level of residual supply chain disruptions that we are actively managing to meet our ~~second half 2022~~ production timelines and that may constrain our ability to capture additional growth opportunities, beyond our established projections, from customers who would otherwise want to increase their safety stock of the products that we produce.

We also continue to closely monitor global economic developments ~~related to COVID-19 and other diseases~~ and geopolitical conflicts, such as the conflict between Russia and Ukraine, which continue to have adverse effects on the U.S. and global ~~markets.~~markets and supply chain.

~~Due~~We have begun to ~~these and other factors, we anticipate~~see the effects of a general slowdown in clinical development activity as a result of clinical failures and/or a lack of adequate funding to go forward. We are making efforts to adapt to these market changes, including a reconfiguration of our business development team to be better positioned in the longer-term by focusing on account management roles and replacing lost positions in strategic focus areas. The slowdown has caused us to experience reductions to our backlog during the first half of 2023. Going forward, ~~which~~the slowdown and/or the reconfiguration may cause us to experience additional reductions to our backlog and/or a reduction in the number of business development opportunities that we will be able to pursue ~~during 2022.~~ or close in 2023.

We also expect to face continuing inflationary pressures on raw materials, labor and logistics during ~~2022.~~2023. Finally, we ~~expect to be~~were impacted by higher variable base interest rates on our ~~LIBOR-based term loan~~ borrowings under credit agreements during the second half of 2022, and while we believe that we have been able to capture overall interest savings as a result of the December 2022 refinancing, we expect those improvements could be partially offset by that sustained variable base interest rate increases from 2022.

Financial overview

Revenues

We recognize three types of revenue: manufacturing, profit-sharing and ~~research~~development.

As previously disclosed, in May 2023, Lannett, which represented 16% of our revenue in 2022, commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware and ~~development.~~entered into a restructuring support agreement with certain of its lenders. On June 8, 2023, Lannett emerged from the Chapter 11 bankruptcy as a privately-held company under the ownership of its prepetition lenders. While our agreement with Lannett remains in place, at this time we do not know whether Lannett's performance with sales of Verapamil PM will be impacted by these events or might otherwise impact our economics going forward.

Manufacturing

We recognize manufacturing revenue from the sale of products we manufacture for our commercial partners. Manufacturing revenues are recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration we expect to be entitled to as specified in the agreement with the commercial partner, which could include pricing and volume-based adjustments.

Profit-sharing

~~We recognize~~In addition to manufacturing revenue, certain customers who use our technologies are subject to agreements that provide us intellectual property sales-based profit-sharing and/or ~~royalty revenue,~~royalties consideration, collectively referred to as profit-sharing, ~~revenue, related to~~computed on the ~~sale~~net product sales of ~~products by our~~the commercial ~~partners that incorporate our technologies.~~partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. ~~For~~We have determined, that in our arrangements, ~~that include sales-based profit-sharing and~~ the license for intellectual property is ~~deemed to be~~not the predominant item to which the profit-sharing relates, so we recognize revenue when the related sales occur by the commercial partner. For arrangements that include sales-based profit-sharing and the license is not deemed to be the predominant item to which the profit-sharing relates, we recognize revenue when the performance obligation to which the profit-sharing has been allocated has been satisfied, which is upon transfer of control of ~~a product to a customer.~~the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by our commercial partners, which are outside of our control. Factors causing price adjustments by our commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing.

~~Research and development~~

~~Research and development~~21

Development

Development revenue includes services associated with formulation, process development, clinical trial ~~material and clinical trial support~~materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms.

In contracts that specify milestones, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which we have continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within our control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received.

In contracts that require revenue recognition over time, we utilize input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications, and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request.

Cost of sales and selling, general and administrative expenses

Cost of sales consists of inventory costs, including production wages, material costs and overhead, and other costs related to the recognition of revenue. Selling, general and administrative expenses ~~consists~~consist of salaries and related costs for administrative, public company ~~costs,~~and business development ~~personnel~~functions as well as legal fees, patent-related expenses and consulting fees. Public company costs include compliance, ~~auditing services,~~audit, tax, ~~services,~~ insurance and investor relations.

In October 2021, we integrated and reorganized our collective employee base to support a multi-site organization. As a result, certain employees in administrative roles are supporting the entire company instead of plant operations. Costs associated with these employees, including employee compensation and other expenses, are classified in selling, general and administrative expenses prospectively from October 1, 2021.

Primarily in the last nine months of 2021, we qualified for approximately $4.4 million of federal employee retention credits that were recognized as offsets to expense. We will not recognize any such expense offsets in 2022.

Amortization of intangible assets

Historically, we recognized amortization expense related to an intangible asset for our profit-sharing and contract manufacturing relationships on a straight-line basis over an estimated useful life of six years. Amortization stopped when the intangible asset reached the end of its useful life in April 2021. With the acquisition of IriSys, weWe are recognizing amortization expense related to acquired customer relationships, backlog and trademarks and trade names on a straight-line basis over estimated useful lives of 7,7.0, 2.4, and 1.5 years, respectively.

Interest expense

Interest expense for the ~~periods~~current period presented primarily relates to our ~~Athyrium~~new term loan borrowing with Royal Bank of Canada originally funded at $36.9 million and the financial liability related to the sale and leaseback of our commercial manufacturing campus in Gainesville, Georgia for gross proceeds of $39.0 million. Interest expense for the prior period presented primarily relates to the $100.0 million senior secured term loans with Athyrium Opportunities III Acquisition LP and the amortization of related financing costs. ~~In addition, following the acquisition~~

As a result of ~~IriSys, there is additional~~these changes, interest expense ~~related~~was lower in the first half of 2023 and will continue to be lower in future periods due to the lower amount of aggregate principal and lower variable interest onmargins as compared to the ~~sellers note which was a component of the IriSys acquisition purchase price.~~Athyrium borrowings.

Net operating losses and tax carryforwards

As of December 31, ~~2021,~~2022, we had federal net operating loss, or NOL, carry forwards of approximately ~~$135.9~~$125.6 million, ~~$127.7 million~~substantially all of which are subject to annual limitations following a December 2022 change in control and have an indefinite carry forward period. ~~The remaining $8.2 million of federal NOL carry forwards, $137.7~~We also had $135.4 million of state NOL carry forwards ~~and federal and state research and development tax credit carryforwards of $4.6 million are also~~ available to offset future taxable income ~~but they~~that will begin to expire at various dates beginning in 2028 if not utilized. We believe that it is more likely than not that ~~the~~our deferred income tax assets ~~associated with our U.S. operations~~ will not be realized, and as such, there is a full valuation ~~allowance against our U.S. deferred tax assets.~~allowance.

Key indicators of performance

To evaluate our performance, we monitor a number of industry-standard key indicators such as:

•

Safety and human capital management, as measured by recordable injuries, good saves and employee retention;

•

Operational excellence, as measured by the percentage of our orders that are delivered on-time and in full;

•

New business growth, as measured by value of new contracts signed; and

•

Financial operating results, as measured by revenue and EBITDA, as adjusted.

EBITDA, as adjusted, is a non-GAAP measure that we discuss and reconcile to its nearest GAAP measure elsewhere in our public financial reporting. We believe that supplementing our financial results presented in accordance with GAAP with non-GAAP measures is useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations ~~that provide a more complete~~and gaining an understanding of our business.

Results of operations

Comparison of second quarters ~~2022~~2023 and ~~2021~~2022


	Three months ended June 30,						Three months ended June 30,
(in millions)	2022			2021			2023			2022
Revenue	$	23.2		$	18.0		$	21.8		$	23.2
Operating expenses:
Cost of sales (excluding amortization of intangible assets)		17.5			12.3
Cost of sales								17.3			17.5
Selling, general and administrative		5.2			3.8			5.3			5.2
Amortization of intangible assets		0.2			0.1			0.2			0.2
Total operating expenses		22.9			16.2			22.8			22.9
Operating income		0.3			1.8
Operating (loss) income								(1.0	)		0.3
Interest expense		(3.4	)		(4.0	)		(2.3	)		(3.4	)
Gain on extinguishment of debt		—			3.4
Net (loss) income	$	(3.1	)	$	1.2
Interest income								0.1			—
Loss before income taxes								(3.2	)		(3.1	)
Income tax expense								—			—
Net loss							$	(3.2	)	$	(3.1	)

Revenue. The ~~increase~~decrease of ~~$5.2~~$1.4 million was primarily driven by ~~an increase~~a decrease in ~~European Ritalin LA demand~~revenue from our largest commercial customer, Teva, due to a scheduled shutdown of our packaging line to implement the upgrades required to comply with new serialization aggregation compliance standards. In addition, the manufacturing revenue associated with then new customer, ~~InfectoPharm,~~InfectoPharm’s, inventory-build during the second quarter of 2022, was greater than the normalized quarterly revenue ~~resulting from~~recorded in the ~~acquisition~~second quarter of ~~IriSys, as well as higher~~2023. These reductions in revenue were partially offset by increased pre-commercial development revenues from our clinical trial materials business. These increases were partially offset by declining revenues from Lannett’s commercial sales of Verapamil PM products compared to the prior year. In an effort to address this decline, we recently executed an amendment to our license and supply agreement with Lannett for the marketing of Verapamil PM and Verelan products subsequent to the end of the period, which provides overall improved economics for Societal and is expected to strengthen revenues from Lannett in the second half of the year despite the declines experienced in the first half of the year.technology transfer projects.

Cost of sales. The ~~increase~~decrease of ~~$5.2~~$0.2 million was primarily due to ~~costs associated with operating the San Diego facility acquired from IriSys and increased costs tied to the increased~~lower commercial manufacturing revenue ~~during~~based on the ~~quarter. In addition, in 2021, we received certain employment incentive tax credits that were not repeated in 2022 resulting in increased expense in 2022. These increases were partially~~timing of the serialization aggregation compliance project offset by higher fixed costs primarily to support the ~~reallocation of expenses reflecting the post-acquisition organizational structure. Prior to October 1, 2021, these employees supported~~newly installed aseptic fill/finish line that has expanded our ~~plant operations and were classified in cost of sales.~~capabilities.

Selling, general and administrative. ~~The increase of $1.4 million was primarily related to increased personnel costs tied to~~Selling, general and administrative expenses were relatively consistent for the ~~reallocation of expenses reflecting the post-acquisition organizational structure (see cost of sales above) and integration costs associated with the IriSys integration.~~periods presented.

Amortization of intangible assets. The increase of $0.1 million was the result of the amortization related to the acquisition of IriSys for acquired customer relationships, backlog and trademarks and trade names partially offset by the amortization of CDMO royalties and contract manufacturing relationships acquired in 2015 ending on April 10, 2021.

~~Interest expense.~~ The decrease of $0.6 million was primarily due to reduced non-cash financing expense and increased capitalized interest. This decrease was partially offset by an increase in interest from the debt portion of the IriSys acquisition purchase price.

~~Gain on extinguishment of debt.~~ In June 2021, the promissory note with PNC Bank under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020, or the PPP Note, and all accrued interest thereon was forgiven.

~~Comparison of six months ended 2022 and 2021~~

Six months ended June 30,

(in millions)
2022

2021

Revenue
$
44.3

$
34.8

Operating expenses:

Cost of sales (excluding amortization of intangible assets)

33.6

26.7

Selling, general and administrative

10.9

8.5

Amortization of intangible assets

0.4

0.7

Total operating expenses

44.9

35.9

Operating loss

(0.6
)

(1.1
)
Interest expense

(6.8
)

(7.8
)
Gain on extinguishment of debt

—

3.4

Net loss
$
(7.4
)

$
(5.5
)

~~Revenue.~~ The increase of $9.5 million was primarily driven by revenue resulting from the acquisition of IriSys as well as higher revenues from our clinical trial materials business. In addition, there was an increase in European Ritalin LA demand from our new customer InfectoPharm as well as an increase in revenue from our largest commercial customer Teva, correlated with pull through in demand resulting from market share gains against the sole competitor for the Verapamil SR products. The increase in revenue was partially offset by a decline in revenue from Lannett’s commercial sales of the Verapamil PM products.

~~Cost of sales.~~ The increase of $6.9 million was primarily due to the acquisition of the San Diego facility and certain 2021 employment incentive tax credits that were not repeated in 2022 resulting in increased expense in 2022. These increases were partially offset by the reallocation of expenses reflecting the post-acquisition organizational structure. Prior to October 1, 2021, these employees supported our plant operations and were classified in cost of sales.

~~Selling, general and administrative.~~ The increase of $2.4 million was primarily related to increased personnel costs tied to the reallocation of expenses and integration costs associated with the IriSys integration. These increases were offset by lower stock-based compensation expense.

~~Amortization of intangible assets.~~ ~~The decrease of $0.3 million was the result of the amortization of CDMO royalties and contract manufacturing relationships acquired in 2015 ending on April 10, 2021 partially offset by the~~ amortization related to the acquisition of IriSys for acquired customer relationships, backlog and trademarks and trade names.

Interest expense. The decrease of ~~$1.0~~$1.1 million was primarily due to a significantly reduced ~~non-cash financing expense~~amount of aggregate principal and ~~increased capitalized interest. Also contributing~~lower interest rates under the company's refinanced debt as compared to the ~~reduction~~borrowings outstanding during the period ended June 30, 2022.

Comparison of six months ended 2023 and 2022


	Six months ended June 30,
(in millions)	2023			2022
Revenue	$	43.3		$	44.3
Operating expenses:
Cost of sales		36.6			33.6
Selling, general and administrative		9.9			10.9
Amortization of intangible assets		0.4			0.4
Total operating expenses		46.9			44.9
Operating loss		(3.6	)		(0.6	)
Interest expense		(4.4	)		(6.8	)
Interest income		0.2			—
Loss before income taxes		(7.8	)		(7.4	)
Income tax expense		0.1			—
Net loss	$	(7.9	)	$	(7.4	)

Revenue. The decrease of $1.0 million was primarily driven by the decreases in ~~interest was the successful refinancing~~revenues from Teva and ~~reduced term loan borrowings under the Credit Agreement with Athyrium as well as a decrease in the LIBOR base rate of interest on our term loans under the Credit Agreement. These decreases~~InfectoPharm, which were partially offset by an increase in ~~interest from the debt portion of the IriSys acquisition purchase price.~~pre-commercial development revenues, as described above.

~~Gain on extinguishment~~Cost of ~~debt.~~ sales.In The increase of $3.0 million was primarily due to mix of revenue and related fixed cost absorption, including increased costs associated with the new aseptic fill/finish line that has expanded our capabilities and increased material costs..

Selling, general and administrative. The decrease of $1.0 million was primarily related to lower public company costs and administrative costs than the prior year.

Amortization of intangible assets. The amortization related to the acquisition of IriSys for acquired customer relationships, backlog and trademarks and trade names.

Interest expense. The decrease of $2.4 million was primarily due to a significantly reduced amount of aggregate principal and lower interest rates under the company's refinanced debt as compared to the borrowings outstanding during the period ended June ~~2021, the PPP Note and all accrued interest thereon was forgiven.~~30, 2022.

Liquidity and capital resources

At June 30, ~~2022,~~2023, we had ~~$15.5~~$4.7 million in cash and cash equivalents. Our credit agreement with Royal Bank of Canada, as amended, contains a quarterly minimum liquidity requirement of $4.0 million through June 30, 2024. Our ability to continue to comply with the minimum liquidity requirement is subject to our success in implementing certain cost control measures, reducing capital expenditures and managing working capital in order to improve our ongoing financial performance and our liquidity position.

Since our inception, we have financed our operations and capital expenditures primarily from results of operations, ~~and~~from the issuance of equity and ~~debt.~~debt, and recently, to a lesser extent, from real estate transactions. During the first half of ~~2022,~~2023, our capital expenditures were ~~$3.3~~$5.5 million to maintain, scale and support ~~our~~ expansion of our capabilities.

See Part II, Item 5 for information about an amendment to the Credit Agreement that occurred subsequent to June 30, 2023.

We are currently party to a credit agreement with ~~Athyrium,~~Royal Bank of Canada, or the Credit Agreement, ~~which has been fully drawn.~~for a term loan originally funded at $36.9 million. The ~~Credit Agreement requires us~~principal is being repaid in quarterly amounts, including $2.3 million, $3.2 million and $0.9 million to ~~repay~~be paid during the twelve months ending June 30, 2024, 2025 and 2026, respectively. The final payment of all remaining outstanding principal ~~amount of $100.0 million~~is due on December 31, 2023. The Credit Agreement also includes certain financial covenants that the Company will need to satisfy on a monthly and quarterly basis, including: (i) maintaining a permitted net leverage ratio, calculated as our indebtedness, net of cash and cash equivalents, divided by EBITDA, each as defined in the Credit Agreement; and (ii) a minimum amount of cash and cash equivalents on hand.16, 2025.

23Subject to certain exceptions, we are required to make mandatory prepayments with the cash proceeds received in respect of asset sales, certain equity sales, extraordinary receipts, debt issuances, upon a change of control and specified other events. Additionally, we are obligated by December 14, 2023 to complete the sale of certain real property adjacent to our Gainesville, Georgia manufacturing campus. If that property is not sold by December 14, 2023, we will be required to pay a fee of $0.4 million and increase each of our quarterly principal payments by $0.2 million until that property is sold and any mandatory principal prepayment is made.

In September 2022, we signed a sales and purchase agreement to sell approximately 121 acres of land adjacent to our Gainesville, Georgia manufacturing campus for expected proceeds of $9.1 million, which we are obligated to use to repay outstanding balances on the Credit Agreement. The land sale is expected to close in the first half of 2024. Until closing, the sale of the land is subject to customary closing conditions for transactions of this type, including completion of title and environmental due diligence and receipt of certain zoning approvals and permits.

The pharmaceutical industry is experiencing a slowdown in clinical development activities resulting from reduced cash funding and other liquidity resources and we are experiencing higher rates of customer attrition and development program delays that caused us to revise our 2023 earnings and cash projections during the second quarter of 2023. As a result of these factors, we took actions to amend our debt agreements to align financial covenants and other terms of the indebtedness with our revised projections. Absent these amendments, we would not have been able to conclude that it was probable that we would comply with the provisions of our debt agreements through August 14, 2024.

We believe that our results of operations will allow us to comply with the financial and other covenants and contractual requirements of the agreements for at least the next twelve months. Our ability to comply is subject to our success in implementing certain cost control measures, reducing capital expenditures and managing working capital in order to improve our ongoing financial performance and our liquidity position.

We may extend and or supplement the actions we are ~~also party~~taking if we continue to ~~an amended common stock purchase agreement~~experience adverse conditions described above, among others, that might impact the forecasted performance. If we are unable to achieve the results required to comply with ~~Aspire Capital Fund LLC, or Aspire Capital. The amended agreement provides that, upon~~ the terms of our credit agreement in one or more quarters over the next twelve months, we may be required to take specific actions in addition to those described above, including but not limited to, additional cost control measures, or alternatively, seeking an amendment or waiver from our lenders. Obtaining a waiver or an amendment is not within our control, and ~~subject~~if unsuccessful, the lenders may exercise the rights available to the conditions and limitations set forth in the agreement, Aspire Capital is committed to purchase, at our sole election, up to an aggregate value of $41.2 million in shares of common stock. As of June 30, 2022, there is availability to issue up to $30.0 million or 6,199,299 shares of common stockthem under the ~~2019 Common Stock Purchase Agreement.~~credit agreement.

We may require additional financing or choose to refinance certain of these instruments, which could include ~~debt refinancing, sale of real estate and/or other assets,~~ strategic development, licensing activities and/or marketing arrangements, ~~or through~~ public or private sales of equity or debt securities ~~from time to time.~~or debt refinancing. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Further, our ability to access capital market or otherwise raise capital may be adversely impacted by potential worsening global economic conditions ~~geopolitical conflicts,~~ and the recent disruptions to, and volatility in, financial markets in the United States and worldwide, ~~resulting from~~including as a result of diseases, geopolitical conflicts, recent liquidity constraints or failures and instability in U.S. and international financial banking systems on the ~~ongoing COVID-19 pandemic and the conflict between Russia and Ukraine.~~global financial markets. Additional debt or equity financing, if available, may be dilutive to the holders of our common stock and may involve significant cash payment obligations and covenants that restrict our ability to operate our business or to access ~~capital.~~capital, and may further restrict dividend payments.

Sources and uses of cash


	Six months ended June 30,						Six months ended June 30,
(amounts in millions)	2022			2021			2023			2022
Net cash (used in) provided by:
Net cash used in:
Operating activities	$	(6.1	)	$	2.7		$	(1.6	)	$	(6.1	)
Investing activities		(3.3	)		(2.1	)		(5.5	)		(3.3	)
Financing activities		(0.3	)		21.3			(3.1	)		(0.3	)
Total	$	(9.7	)	$	21.9		$	(10.2	)	$	(9.7	)

Cash flows from operating activities represents our net loss as adjusted for stock-based compensation ~~depreciation,~~expense, non-cash interest expense, ~~and~~depreciation expense, amortization of ~~intangibles~~intangible assets and deferred income tax expense as well as changes in operating assets and liabilities. The ~~increase~~$4.5 million decrease in cash flows used for operating activities in ~~operations in 2022~~2023 compared to ~~2021~~2022 was primarily due to favorable working capital changes, partially offset by a decrease in ~~stock-based compensation expense in addition to changes in operating assets and liabilities. These included (i) a $3.3 million change in inventory balances due to timing~~earnings exclusive of production and customer orders; (ii) a $1.1 million change in accounts receivable due to increased sales activity; (iii) a $2.3 million change in accrued payroll due to the fact that there were limited cash bonuses paid in 2021 and the effects of payroll period cutoff; and (iv) an additional $2.2 million interest payment that fell in the first quarter of 2022 compared to 2021, partially offset by (v) a $0.5 million reduction of prepaid expenses and other current assets.non-cash items.

Net cash used in investing activities for each period includes capital expenditures to scale and support our expansion of capabilities. With the inclusion of IriSys, we continue to anticipate that 2022 capital expenditures will increase as we continue to maintain our existing capabilities and support the growth of our clinical trials business and other new business acquired from IriSys. We expect to complete a significant capital project during the early second half of 2022 that will enhance our sterile fill and finishing capabilities. If we are unable to complete the capital project according to plan, this could have an adverse impact on our forecasted results.

Net ~~cash provided by financing activities in 2021 changed to net~~ cash used in financing activities ~~in 2022, a change of $21.5~~increased $2.8 million primarily due to ~~the absence of significant activities that occurred in 2021; in the first half of 2021, net proceeds from an issuance of common stock of $32.1 million were partially offset by~~ debt repayments of ~~$10.1~~$0.9 million and ~~related financing cost~~ payments of ~~$0.2 million.~~$2.0 million related to the December 2022 debt refinancing.

Forward-looking factors

Our future use of operating cash and capital requirements will depend on many forward-looking factors, including the following:

•

the extent to which we in-license, acquire or invest in products, businesses and technologies;

•

the timing and extent of our manufacturing and capital expenditures;

•

our ability to maintain or expand our relationships and contracts with our commercial partners;

•

our ability to grow and diversify our business with new customers, including our ability to meet desired project outcomes with development customers;

•

our ability to regain profitability;

•

our ability to comply with stringent U.S. & foreign government regulation in the manufacture of pharmaceutical products, including cGMP and ~~U.S.~~ DEA requirements;

•

our ability to raise additional funds through equity or debt financings or sale of real estate or other assets;

•

the costs of maintaining, enforcing and defending intellectual property claims;

•

~~our ability to regain,~~ and ~~maintain, compliance with the Nasdaq continued listing standards;~~

•

the extent to which health epidemics and other outbreaks of communicable diseases, ~~including the ongoing COVID-19 pandemic, could disrupt our operations or materially and adversely affect our business and financial conditions; and~~

•

~~the extent to which~~ inflation, global instability, including political instability ~~such as a deterioration in the relationship between the US~~ and ~~China or escalation in conflict between Russia and Ukraine, including~~ any ~~additional~~ resulting sanctions, export controls or other restrictive actions that may be imposed by the U.S. and/or other countries against governmental or other entities ~~in, for example, Russia,~~ may disrupt our business operations or financial condition or the financial condition of our customers and suppliers.

We anticipate raising funds from real estate asset sales to reduce our outstanding debt principal. There are a number of risks and uncertainties that could impact real estate values and or our ability, if any, to successfully monetize the sale of any non-core real-estate assets including, but not limited to, market forces, economic conditions, revenue concentration, debt levels, geographic location, interest rates, results of engineering plans, geotechnical surveys, coverage density, physical characteristics of the land (e.g. rock, wetlands delineation, streams, powerlines, topography, zoning), ability to reach acceptable contractual terms and obtaining the required approvals and release(s) from our senior secured lender.

We may ~~also~~ use existing cash and cash equivalents on hand, additional debt, equity financing, sale of real-estate or other assets or out-licensing revenue or a combination thereof to fund our operations or acquisitions. If we increase our debt levels, we might be restricted in our ability to raise additional capital and might be subject to financial and restrictive covenants. ~~Our~~If we issue additional equity in future periods, our shareholders may experience ~~dilution as a result of the issuance of additional equity or debt securities.~~dilution. This dilution may be significant depending upon the amount of equity or debt securities that we issue and the prices at which we issue any securities.

Contractual commitments

The table below reflects our contractual commitments as of June 30, ~~2022:~~2023:


	Payments due by period										Payments due by period
(in millions)	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years		Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Debt obligations (1):
Principal	$	106.5	$	2.0	$	104.1	$	0.1	$	0.3	$	40.4	$	7.1	$	33.0	$	0.1	$	0.2
Interest		15.0		9.7		5.1		0.1		0.1		8.3		3.5		4.7		0.1		—
Purchase obligations (2)		10.6		0.7		9.9		—		—		8.0		7.4		0.6		—		—
Operating leases (3)		9.9		1.2		2.4		2.1		4.2		8.9		1.2		2.3		2.3		3.1
Other long-term liabilities ~~(4)~~(5)		—		—		—		—		—		92.8		3.6		7.5		7.9		73.8
Total	$	142.0	$	13.6	$	121.5	$	2.3	$	4.6	$	158.4	$	22.8	$	48.1	$	10.4	$	77.1

(1)

Debt obligations consist of principal ~~an exit fee of 1% of that principal,~~ and interest on ~~$100.0~~$36.0 million of an outstanding term ~~loans~~loan under our credit facility with ~~Athyrium, $6.1~~Royal Bank of Canada, $4.1 million of notes issued to the former members of IriSys and ~~another~~a small ~~loan.~~finance lease. Because the ~~Athyrium~~Royal Bank of Canada term ~~loans bear~~loan bears interest at a variable rate based on ~~LIBOR,~~SOFR, we estimated future interest commitments utilizing the ~~LIBOR~~SOFR rate as of June 30, ~~2022.~~2023. In accordance with U.S. GAAP, the future interest obligations are not recorded on our consolidated balance sheet.

In August 2022, we amended our credit agreeement and note issued to the former members of IriSys, which resulted in no changes to the presentation of the table. See Part II, Item 5 of this Quarterly Report on Form 10-Q.

(2)

Purchase obligations consist of cancelable and non-cancelable purchase commitments related to inventory, capital expenditures and other goods or services. In accordance with U.S. GAAP, these obligations are not recorded on our consolidated balance sheets.

(3)

We are party to two operating leases for development facilities in California and Georgia that end in 2031 and 2025, respectively. The leases each include options to extend at our discretion.

(4)

We are party to a lease for a DEA-licensed facility in Georgia that ends in 2042. The lease includes the option to extend at our discretion. The principal component of this obligation is classified as a liability under U.S. GAAP, therefore we did not present it as an operating or capital lease in the table.

(5)

We have entered into employment agreements with each of our ~~named~~ executive officers that provide for, among other things, severance commitments of up to ~~$1.3~~$1.4 million should we terminate the ~~named~~ executive officers for convenience or if certain events occur following a change in control. In addition, we would be subject to other contingencies of up to ~~$3.8~~$4.6 million in the aggregate if certain events occur following a change in control. Because these obligations are contingent, the amounts are not included in the table above.

Critical accounting policies and estimates

Our critical accounting policies and estimates are disclosed in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report.

Item 3. Quantitative and qualitative disclosures about market risk

There has been no material change in our assessment of our sensitivity to market risk described in the Annual Report.

Item 4. Controls and procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of June 30, ~~2022.~~2023. We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure.

A control system, no matter how well conceived and operated, can provide only reasonable, and not absolute, assurance that the objectives of the control system will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. However, our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of June 30, ~~2022,~~2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in internal control over financial reporting

There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal proceedings.

Information regarding legal and regulatory proceedings is set forth in note 7 to our consolidated financial statements included in Part I, Item 1 of this Quarterly Report, and is incorporated by reference herein.

We are also engaged in various other legal actions arising in the ordinary course of our business (such as, for example, proceedings relating to employment matters or the initiation or defense of proceedings relating to intellectual property rights) and, while there can be no assurance, we believe that the ultimate outcome of these other legal actions will not have a material adverse effect on our business, results of operations, financial condition or cash flows.

Item 1A. Risk factors.

Investing in our securities involves certain risks. In addition to any risks and uncertainties described elsewhere in this Quarterly Report, investors should carefully consider the risks and uncertainties discussed in Part I, Item 1A. “Risk Factors” in our Annual Report. These risks are not the only risks that could materialize. Other than as set forth below, there have been no material changes in our risk factors from those previously disclosed in our ~~2021~~ Annual Report and Quarterly Report for the quarter ended March 31, ~~2022.~~2023.

Our revenues are dependent on a small number of commercial partners, and the loss of any one of these partners, or a decline in their orders, may adversely affect our business.

We are dependent on a small number of commercial partners, with our four largest customers (Teva Pharmaceutical Industries, Inc., or Teva, Novartis Pharma AG, or Novartis, Lannett Company, Inc., or Lannett, and InfectoPharm Arzneimittel und Consilium GmbH, or InfectoPharm) having generated 77% of our revenues for the year ended December 31, 2022, of which Teva generated 34%, Novartis generated 18%, Lannett generated 16%, and InfectoPharm generated 9%. In May 2023, Lannett, which represented 16% of our revenue in 2022, commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware and entered into a restructuring support agreement with certain of its lenders. On June 8, 2023, Lannett emerged from the Chapter 11 bankruptcy as a privately-held company under the ownership of its prepetition lenders. While our agreement with Lannett remains in place, at this time we do not know whether Lannett's performance with sales of Verapamil PM post-bankruptcy will impact our economics going forward. In addition, Novartis has provided us notice it intends to assign our agreement to Sandoz, its generic division, as part of the public spin-off of Sandoz. Such developments with Lannett and Novartis, as well as any increases in competition in the market, pricing adjustments, significantly reduced purchasing volume or financial difficulties (for example, the Lannett bankruptcy) with any one or more of our key commercial partners could adversely affect our revenue.

Our profit sharing, royalty, and manufacturing revenues also depend on the ability of our commercial partners to effectively market and sell their products to their customers. A commercial partner may choose to devote its efforts to its other products or reduce or fail to devote the necessary resources to provide effective sales and marketing support for the products we manufacture and supply. Furthermore, the acquisition of or change in strategy by one of our customers could impact projects we are currently working on or planning to work on in the future. Our commercial partners face competition from other pharmaceutical companies for sales of products to end users. Competition from sellers of generic drugs is a major challenge for our commercial partners, and the loss or expiration of intellectual property rights for the products we manufacture can have a significant adverse effect on their sales volume and price. Our commercial partners have also experienced difficulties in recent years as the pharmaceutical industry was impacted by the COVID-19 pandemic, labor shortages, supply chain shortages, inflationary pressures and geopolitical turmoil. Similar pressures could lead a partner to discontinue a product, make pricing changes or change ordering patterns. In addition, as pharmaceutical product pricing faces scrutiny by governments, legislative bodies and enforcement agencies, our commercial partners may lower their prices or adopt cost-savings measures which could be passed on to us or otherwise impact our profit-sharing revenues. Further, any commercial partner may divest the product we manufacture for them in whole or in certain markets, which may involve termination of our contract with such partner or the assignment of such contract to a new partner who may not be as effective at selling or commercializing such product. Pricing changes and any significant reduction, delay or cancellation of orders from our commercial partners could adversely affect our revenues.

We are currently listed on the Nasdaq Capital Market. If we are unable to ~~regain compliance with the~~maintain listing ~~standards~~ of our securities on Nasdaq or any stock exchange, our ~~common~~ stock ~~may become delisted, which~~price could ~~have a material adverse effect on~~be adversely affected and the liquidity of our ~~common stock.~~stock and our ability to obtain financing could be impaired and it may be more difficult for our shareholders to sell their securities.

~~The listing standards of~~Although our common stock is currently listed on the Nasdaq ~~provide that a company, in order~~Capital Market, we may not be able to ~~qualify for continued~~continue to meet the exchange’s minimum listing ~~must maintain a minimum closing bid price~~requirements or those of ~~$1.00 and satisfy standards relative to minimum shareholders’ equity, minimum market value of publicly held shares and various additional requirements.~~any other national exchange. On ~~June 27, 2022,~~May 23, 2023, we received a deficiency letter from the Nasdaq Listing Qualifications Department of the Nasdaq ~~or the Staff,~~Stock Market LLC notifying us that, for the ~~last~~ 30 consecutive business ~~days,~~day period preceding the date of the letter, the closing bid price for our common stock ~~had closed~~was below the minimum $1.00 per share ~~requirement~~required for continued ~~inclusion~~listing on ~~Nasdaq.~~

the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq deficiency letter only pertains to our stock price, and there are no other deficiencies related to our ongoing listing on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been ~~provided a period of~~given 180 calendar days, or until ~~December 26, 2022, in which to regain compliance. In order~~November 20, 2023, to regain compliance with Rule 5550(a)(2). If at any time before November 20, 2023, the ~~minimum bid price requirement, the closing~~ bid price of our common stock ~~must be~~closes at ~~least~~ $1.00 per share or more for a minimum of ~~ten~~10 consecutive business days, ~~during this 180-day period. In~~ the ~~event~~Nasdaq Listing Qualifications Department will provide written confirmation that we have achieved compliance.

If we do not regain compliance ~~within this 180-day period,~~with Rule 5550(a)(2) by November 20, 2023, we may be ~~eligible to seek an additional compliance period of~~afforded a second 180 calendar ~~days if~~day period to regain compliance. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq ~~with~~Capital Market, except for the ~~exception of the~~minimum bid price requirement. ~~However, if it appears to the Staff that we will not be able to cure the deficiency, Nasdaq will provide notice to us that we will not be eligible for the additional compliance period and~~

The delisting of our common stock from the Nasdaq Capital Market may make it more difficult for us to raise capital on favorable terms in the future. Such a delisting would likely a result in a reduction in some or all of the following may occur, each of which could have a material adverse effect on our shareholders and may impair your ability to sell or purchase our common stock when you wish to do so:

•

the liquidity of our common stock;

•

the market price of our common stock;

•

our ability to obtain financing for the continuation of our operations;

•

the number of investors that will consider investing in our common stock;

•

the number of market makers in our common stock;

•

the availability of information concerning the trading prices and volume of our common stock; and

•

the number of broker-dealers willing to execute trades in shares of our common stock.

Further, if we were to be delisted from the Nasdaq Capital Market and we are unable to obtain listing on another national securities exchange, our common stock would cease to be recognized as covered securities and we would be subject to ~~delisting. We would then be entitled to appeal the determination to a Nasdaq Listing Qualifications Panel and request a hearing.~~

~~There can be~~regulation in each state in which we offer our securities. Moreover, there is no assurance that any actions that we ~~will be able~~take to ~~regain~~restore our compliance with the minimum bid price requirement would stabilize the market price or ~~maintain compliance with~~improve the other Nasdaq listing requirements. If we do not regain compliance with the Nasdaq continuing listing requirements, our common stock will be delisted from Nasdaq and it could be more difficult to buy or sell our securities and to obtain accurate quotations, and the priceliquidity of our common stock, ~~could suffer a material decline. In addition, a delisting would impair~~prevent our ~~ability to raise capital through~~common stock from falling below the ~~public markets, could deter broker-dealers from making a market in~~minimum bid price required for continued listing again, or ~~otherwise seeking or generating interest in our securities and might deter certain institutions and persons from investing in our securities at all.~~prevent future non-compliance with Nasdaq’s listing requirements.

Item 2. Unregistered sales of equity securities and use of proceeds.

None.

Item 3. Defaults upon senior securities.

None.

Item 4. Mine safety disclosures.

Not applicable.

Item 5. Other information.

~~None.~~Amendment to Seller Note

On August 13, 2023, the Company and IriSys, Inc. (the “Seller”) entered into a First Amendment to Subordinated Promissory Note (the “Note Amendment”) pursuant to which the parties agreed to defer the due date of the payment due to the Seller on August 13, 2023 of approximately $2.0 million of principal, plus accrued interest, under the Subordinated Promissory Note to the earlier of (i) June 24, 2024; and (ii) the date on which the Company completes its previously announced sale of certain land at its Gainesville, Georgia location. In addition, the Note Amendment provides that the Company will pay up to $1.0 million of the deferred payment upon completion of certain financings. In consideration of Seller’s entry into the Note Amendment, the Company paid the Seller a $150,000 amendment fee, agreed to pay up to $50,000 of Seller’s legal fees in connection with the Note Amendment and issued the Seller a warrant to purchase 100,000 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) at an exercise price of $1.00 with a term of three years (the “Warrant”).

Amendment to the RBC Credit Agreement

On August 13, 2023, the Company amended its Credit Agreement with Royal Bank of Canada pursuant to a Second Amendment and Waiver to Credit Agreement (the “Credit Agreement Amendment”). Pursuant to the terms of the Credit Agreement Amendment: (i) the Company is obligated to make a $7.5 million mandatory principal prepayment upon the sale of the Company’s real property located adjacent to its Gainesville, Georgia manufacturing campus; (ii) effective for the fiscal quarter ending September 30, 2023 through the quarter ending March 31, 2024, the net leverage ratio is permitted to be no greater than 3.75:1.00, stepping down to 2.75:1.00 for each quarter thereafter; (iii) effective for the quarter ending September 30, 2023, the permitted fixed charge coverage ratio was decreased to 1.00:1.00, which increases to 1.05:1.00 for each quarter thereafter; (iv) the permitted quarterly minimum liquidity amount of $4.0 million was extended through June 30, 2024, after which the quarterly minimum liquidity amount increases to $4.5 million through September 30, 2024, and increases to $5.0 million through September 30, 2025; (v) a new permitted monthly minimum liquidity amount was established applicable to all month-end dates, other than quarter-end dates, and equal to $1.5 million; and (vi) beginning with the quarter ending December 31, 2023, funded capital expenditures, as defined, cannot exceed $9.0 million in the aggregate for the preceding twelve-month period. In connection with the amendment, the Company paid an amendment fee of $90,000.

The foregoing description of the Note Amendment, the Credit Agreement Amendment and the Warrant does not purport to be complete and is qualified in its entirety by reference to the Note Amendment, the Amendment and the Warrant, copies of which are filed as Exhibits 10.1, 10.2 and 4.2 hereto and are hereby incorporated herein by reference.

Item 6. Exhibits.

(a)

The following exhibits are filed herewith or incorporated by reference herein:

EXHIBIT INDEX

~~EXHIBIT INDEX~~


Exhibit No.	Description	Method of filing
4.1	Common Stock Purchase Warrant in favor of Warberg WF XI LP (as assigned by OTA LLC)	Filed herewith
4.2	Common Stock Purchase Warrant in favor of IriSys, Inc.	Filed herewith
10.1	First Amendment ~~No. 3~~ to ~~License and Supply~~Subordinated Promissory Note	Filed herewith
10.2	Second Amendment to Credit Agreement dated as of ~~July 1, 2022~~August 13, 2023, by ~~and among~~ Societal CDMO, ~~Gainesville LLC and Lannett Company,~~ Inc. in favor of Royal Bank of Canada	Filed herewith
31.1	Rule 13a-14(a)/15d-14(a) certification of Principal Executive Officer	Filed herewith
31.2	Rule 13a-14(a)/15d-14(a) certification of Principal Financial and Accounting Officer	Filed herewith
32.1	Section 1350 certification, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101 INS	XBRL Instance Document	Filed herewith
101 SCH	XBRL Taxonomy Extension Schema	Filed herewith
101 CAL	XBRL Taxonomy Extension Calculation Linkbase	Filed herewith
101 DEF	XBRL Taxonomy Extension Definition Linkbase	Filed herewith
101 LAB	XBRL Taxonomy Extension Label Linkbase	Filed herewith
101 PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	SOCIETAL CDMO, INC.

Date: August ~~10, 2022~~14, 2023	By:	/s/ J. David Enloe, Jr.
		J. David Enloe, Jr.
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: August ~~10, 2022~~14, 2023	By:	/s/ Ryan D. Lake
		Ryan D. Lake
		Chief Financial Officer
		(Principal Financial and Accounting Officer)


	Date or period	Shares of common stock issued		Gross proceeds		Offering expenses			Net proceeds
Initial public offering	March 12, 2014		4,312,500	$	34,500	$	(4,244	)	$	30,256
Private placement	July 7, 2015		1,379,311		16,000		(1,188	)		14,812
Underwritten public offering	August 19, 2016		1,986,666		14,900		(1,533	)		13,367
Underwritten public offering	December 16, 2016		6,670,000		40,020		(3,132	)		36,888
2018 common stock purchase agreement with Aspire Capital	Year ended December 31, 2018		1,950,000		16,999		—			16,999
2019 common stock purchase agreement with Aspire Capital	Fourth quarter 2020		4,690,972		11,172		(78	)		11,094
Share issuance agreement for amendment 5 to Credit Agreement	February 2021		2,202,420		9,338		(20	)		9,318
Underwritten public offering	May 12, 2021		15,333,332		34,500		(2,397	)		32,103
Issuance of shares for IriSys acquisition	February 2022		9,302,718		20,931		(619	)		20,312


	Contract assets			Contract liabilities
Balance at December 31, 2021	$	8,565		$	2,308
Changes to the beginning balance of contract assets arising from:
Reclassification to receivables as a result of rights to consideration becoming unconditional		(10,518	)		—
Reduction to offset within net contract asset due to recognition of revenue		676			—
Changes in estimate		1,512			—
Contract assets recognized since beginning of period, net of reclassification to receivables and changes in estimates		9,124			—
Changes to contract liabilities:
Amounts billed in advance of contract performance		—			4,275
Revenue recognized		—			(4,367	)
Balance at June 30, 2022	$	9,359		$	2,216